Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
25,000 | 2019-05-06 00:00:00 UTC | Two Healthcare Stocks in the XLV Fund Stand Out | ABBV | https://www.nasdaq.com/articles/two-healthcare-stocks-xlv-fund-stand-out-2019-05-06 | null | null | Healthcare stocks have fallen somewhat out of favor, as tech and faster growing industries have lead the rally in equities this year. There is a prevailing notion that healthcare stocks are defensive, given their business models and the dividends they pay to their shareholders. However, there are standouts in the sec... | In oncology, AbbVie announced a strategic partnership with Teneobio, a biotechnology company that’s developing a new class of biologics for the treatment of cancer, autoimmunity and infectious diseases. For investors looking to bet on individual stocks, Merck & Co (NYSE:MRK) and AbbVie I(NYSE:) look like particularly g... | For investors looking to bet on individual stocks, Merck & Co (NYSE:MRK) and AbbVie I(NYSE:) look like particularly good options. Within the XLV fund, MRK stock makes up 6% of overall holdings and ABBV stock accounts for 3.5% of its assets. Healthcare Stocks to Buy: ABBV ABBV stock hasn’t maintained as much upward mome... | Within the XLV fund, MRK stock makes up 6% of overall holdings and ABBV stock accounts for 3.5% of its assets. For investors looking to bet on individual stocks, Merck & Co (NYSE:MRK) and AbbVie I(NYSE:) look like particularly good options. MRK stock and ABBV stock are primed to bounce back after both dropped slightly... | Within the XLV fund, MRK stock makes up 6% of overall holdings and ABBV stock accounts for 3.5% of its assets. For investors looking to bet on individual stocks, Merck & Co (NYSE:MRK) and AbbVie I(NYSE:) look like particularly good options. MRK stock and ABBV stock are primed to bounce back after both dropped slightly... |
25,001 | 2019-05-01 00:00:00 UTC | Profit from Earnings Volatility With This Biotech Stocks Pairs Trade | ABBV | https://www.nasdaq.com/articles/profit-earnings-volatility-biotech-stocks-pairs-trade-2019-05-01 | null | null | If the trend is your friend, off and on the price chart biotech stocks Merck (NYSE:) and AbbVie (NYSE:) make a great pairing as a sector long and short in MRK stock and ABBV stock. Let me explain.
Earnings and its associated volatility can be a tough trade. I’ve said that before and I’m sure I’ll say it again. There ar... | If the trend is your friend, off and on the price chart biotech stocks Merck (NYSE:) and AbbVie (NYSE:) make a great pairing as a sector long and short in MRK stock and ABBV stock. And that’s the situation facing ABBV stock in today’s market and why it’s time to position for a pair of friendly bullish and bearish trend... | If the trend is your friend, off and on the price chart biotech stocks Merck (NYSE:) and AbbVie (NYSE:) make a great pairing as a sector long and short in MRK stock and ABBV stock. And that’s the situation facing ABBV stock in today’s market and why it’s time to position for a pair of friendly bullish and bearish trend... | If the trend is your friend, off and on the price chart biotech stocks Merck (NYSE:) and AbbVie (NYSE:) make a great pairing as a sector long and short in MRK stock and ABBV stock. Biotech Stocks Short: ABBV Stock The second of our two biotech stocks is AbbVie. And that’s the situation facing ABBV stock in today’s mark... | Biotech Stocks Short: ABBV Stock The second of our two biotech stocks is AbbVie. If the trend is your friend, off and on the price chart biotech stocks Merck (NYSE:) and AbbVie (NYSE:) make a great pairing as a sector long and short in MRK stock and ABBV stock. And that’s the situation facing ABBV stock in today’s mark... |
25,002 | 2019-04-30 00:00:00 UTC | Financial Exchange Stock Talk: Dividend Sensei On AbbVie | ABBV | https://www.nasdaq.com/articles/financial-exchange-stock-talk%3A-dividend-sensei-abbvie-2019-04-30 | null | null | By Dividend Sensei:
See Dividend Sensei's recent article on AbbVie (ABBV) here.
See also Hurco Now Definitely In The Down Cycle on seekingalpha.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Dividend Sensei: See Dividend Sensei's recent article on AbbVie (ABBV) here. See also Hurco Now Definitely In The Down Cycle on seekingalpha.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Dividend Sensei: See Dividend Sensei's recent article on AbbVie (ABBV) here. See also Hurco Now Definitely In The Down Cycle on seekingalpha.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Dividend Sensei: See Dividend Sensei's recent article on AbbVie (ABBV) here. See also Hurco Now Definitely In The Down Cycle on seekingalpha.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Dividend Sensei: See Dividend Sensei's recent article on AbbVie (ABBV) here. See also Hurco Now Definitely In The Down Cycle on seekingalpha.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
25,003 | 2019-04-29 00:00:00 UTC | Better Big Pharma Stock: AbbVie vs. AstraZeneca | ABBV | https://www.nasdaq.com/articles/better-big-pharma-stock-abbvie-vs-astrazeneca-2019-04-29 | null | null | AbbVie (NYSE: ABBV) and AstraZeneca (NYSE: AZN) have a lot in common -- they're just several years out of sync. While AbbVie is headed toward a patent cliff, AstraZeneca has been languishing somewhere near the bottom of the cliff it fell off years ago.
Which of these big pharma stocks has the best chance of outperformi... | AbbVie (NYSE: ABBV) and AstraZeneca (NYSE: AZN) have a lot in common -- they're just several years out of sync. While AbbVie is headed toward a patent cliff, AstraZeneca has been languishing somewhere near the bottom of the cliff it fell off years ago. The case for AbbVie Sales of AbbVie's top-selling drug, Humira hit ... | The case for AbbVie Sales of AbbVie's top-selling drug, Humira hit a high water mark in 2018 at just shy of $20 billion. Investors nervous about AbbVie's ability to offset Humira's upcoming sales declines have pushed the stock price down to just 9.0 times forward earnings expectations. AbbVie (NYSE: ABBV) and AstraZene... | The case for AbbVie Sales of AbbVie's top-selling drug, Humira hit a high water mark in 2018 at just shy of $20 billion. Investors nervous about AbbVie's ability to offset Humira's upcoming sales declines have pushed the stock price down to just 9.0 times forward earnings expectations. AbbVie (NYSE: ABBV) and AstraZene... | Humira still accounts for 56.8% of AbbVie's total revenue, so investors should be concerned. During Q1, AbbVie's share of Imbruvica sales rose 34% to an annualized $4.1 billion and could reach $7 billion by 2023. AbbVie is now waiting for the FDA to hand down a decision about upadacitinib, a tablet for rheumatoid arthr... |
25,004 | 2019-04-27 00:00:00 UTC | Why AbbVie Is in Better Shape Than You Might Think | ABBV | https://www.nasdaq.com/articles/why-abbvie-better-shape-you-might-think-2019-04-27 | null | null | It's rarely a good sign when a company's quarterly revenue drops from the prior-year period. But that's exactly what happened in the first quarter for AbbVie (NYSE: ABBV). The big pharma's sales slipped 1.3% year over year to $7.83 billion. It marked the first quarter in AbbVie's history to report a revenue decline.
Ma... | AbbVie and its partner Roche await another key FDA approval for Venclexta in combination with Gazyva as a first-line treatment for chronic lymphocytic leukemia (CLL). AbbVie President Michael Severino liked what he saw in the phase 2 data for the drug in treating EGFR-amplified glioblastoma multiforme, an aggressive fo... | For full-year 2019, AbbVie expects adjusted EPS growth of 11%. AbbVie thinks the drug could make $6.5 billion annually at its peak. Strong cash flow Last but not least, AbbVie continues to generate exceptionally strong cash flow despite the headwinds for Humira. | AbbVie CFO Robert Michael noted in the company's Q1 conference call that adjusted gross margin increased 310 basis points year over year in Q1 to 83.3% of sales. Timing factors Investors should also know that several timing factors will combine to make 2019 more challenging for AbbVie than the next few years will be fo... | It marked the first quarter in AbbVie's history to report a revenue decline. But that's exactly what happened in the first quarter for AbbVie (NYSE: ABBV). Make no mistake: AbbVie now faces its toughest challenge ever. |
25,005 | 2019-04-26 00:00:00 UTC | 3 Big Stock Charts for Friday: AbbVie, ConocoPhillips and MGM Resorts | ABBV | https://www.nasdaq.com/articles/3-big-stock-charts-for-friday%3A-abbvie-conocophillips-and-mgm-resorts-2019-04-26 | null | null | A back and forth session on Thursday ultimately ended in a stalemate, with the S&P 500 closing a scant 0.04% lower yesterday. The direction of the market’s undertow, if there is one, remains unclear.
Source:
3M (NYSE:) did more damage than any other name, falling nearly 13% after reporting disappointing first-quarter n... | Rather, it’s the stock charts of AbbVie (NYSE:), ConocoPhillips (NYSE:) and MGM Resorts International (NYSE:) that have earned closer looks. AbbVie (ABBV) With just a quick glance, AbbVie looks like it’s in serious trouble. ABBV stock may be better positioned for a rebound than it seems on the surface, however. | Rather, it’s the stock charts of AbbVie (NYSE:), ConocoPhillips (NYSE:) and MGM Resorts International (NYSE:) that have earned closer looks. AbbVie (ABBV) With just a quick glance, AbbVie looks like it’s in serious trouble. ABBV stock may be better positioned for a rebound than it seems on the surface, however. | Rather, it’s the stock charts of AbbVie (NYSE:), ConocoPhillips (NYSE:) and MGM Resorts International (NYSE:) that have earned closer looks. AbbVie (ABBV) With just a quick glance, AbbVie looks like it’s in serious trouble. ABBV stock may be better positioned for a rebound than it seems on the surface, however. | Rather, it’s the stock charts of AbbVie (NYSE:), ConocoPhillips (NYSE:) and MGM Resorts International (NYSE:) that have earned closer looks. AbbVie (ABBV) With just a quick glance, AbbVie looks like it’s in serious trouble. ABBV stock may be better positioned for a rebound than it seems on the surface, however. |
25,006 | 2019-04-25 00:00:00 UTC | AbbVie Inc (ABBV) Q1 2019 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-q1-2019-earnings-call-transcript-2019-04-25 | null | null | Image source: The Motley Fool.
AbbVie Inc (NYSE: ABBV)
Q1 2019 Earnings Call
April 25, 2019, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning and thank you for standing by. Welcome to the AbbVie First Quarter 2019 Earnings Conference Call. All part... | AbbVie Inc (NYSE: ABBV) Q1 2019 Earnings Call April 25, 2019, 9:00 a.m. Welcome to the AbbVie First Quarter 2019 Earnings Conference Call. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-... | Chase -- Executive Vice President, Finance and Administration Geoffrey Christopher Meacham -- Barclays Bank PLC -- Analyst Vamil Kishore Divan -- Credit Suisse AG -- Analyst More ABBV analysis Transcript powered by AlphaStreet This article is a transcript of this conference call produced for The Motley Fool. AbbVie Inc... | AbbVie Inc (NYSE: ABBV) Q1 2019 Earnings Call April 25, 2019, 9:00 a.m. Welcome to the AbbVie First Quarter 2019 Earnings Conference Call. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-... | AbbVie Inc (NYSE: ABBV) Q1 2019 Earnings Call April 25, 2019, 9:00 a.m. Welcome to the AbbVie First Quarter 2019 Earnings Conference Call. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-... |
25,007 | 2019-04-25 00:00:00 UTC | Noteworthy Thursday Option Activity: INTC, RTN, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-intc-rtn-abbv-2019-04-25 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Intel Corp (Symbol: INTC), where a total of 82,236 contracts have traded so far, representing approximately 8.2 million underlying shares. That amounts to about 46.4% of INTC's average daily trading volume over the p... | Particularly high volume was seen for the $85 strike call option expiring May 17, 2019, with 1,067 contracts trading so far today, representing approximately 106,700 underlying shares of ABBV. Below is a chart showing RTN's trailing twelve month trading history, with the $175 strike highlighted in orange: And AbbVie In... | Below is a chart showing RTN's trailing twelve month trading history, with the $175 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 22,965 contracts thus far today. Below is a chart showing ABBV's trailing twelve month trading history, with the $85 strike highlighted in orang... | Below is a chart showing ABBV's trailing twelve month trading history, with the $85 strike highlighted in orange: For the various different available expirations for INTC options, RTN options, or ABBV options, visit StockOptionsChannel.com. Below is a chart showing RTN's trailing twelve month trading history, with the ... | Particularly high volume was seen for the $85 strike call option expiring May 17, 2019, with 1,067 contracts trading so far today, representing approximately 106,700 underlying shares of ABBV. Below is a chart showing RTN's trailing twelve month trading history, with the $175 strike highlighted in orange: And AbbVie In... |
25,008 | 2019-04-25 00:00:00 UTC | What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings | ABBV | https://www.nasdaq.com/articles/what-you-need-know-about-abbvies-surprisingly-strong-q1-earnings-2019-04-25 | null | null | AbbVie (NYSE: ABBV) raised concerns among investors the last time it delivered quarterly results. The drugmaker's January report showed it had missed analysts' estimates on both the top and bottom lines in the fourth quarter, after getting surprised somewhat by its rivals' aggressive pricing of biosimilars to its top-... | The biggest factors behind the increase in non-GAAP earnings were adjustments due to a change in the fair value of contingent consideration and for AbbVie's corporate restructuring. CEO Rick Gonzalez said that the drug "has the potential to set a new standard of care in psoriasis and represents a significant long-term ... | By the numbers AbbVie reported Q1 net revenue of $7.83 billion, down 1.3% from the prior-year period. This was a decline from Q1 2018, when AbbVie reported GAAP net earnings of $2.78 billion, or $1.74 per share. On a non-GAAP adjusted basis, AbbVie's Q1 earnings came in at $2.14 per share -- up 14.4% year over year. | This was a decline from Q1 2018, when AbbVie reported GAAP net earnings of $2.78 billion, or $1.74 per share. On a non-GAAP adjusted basis, AbbVie's Q1 earnings came in at $2.14 per share -- up 14.4% year over year. AbbVie (NYSE: ABBV) raised concerns among investors the last time it delivered quarterly results. | This was a decline from Q1 2018, when AbbVie reported GAAP net earnings of $2.78 billion, or $1.74 per share. On a non-GAAP adjusted basis, AbbVie's Q1 earnings came in at $2.14 per share -- up 14.4% year over year. AbbVie announced on Wednesday that the U.S. Food and Drug Administration had approved Skyrizi (risankizu... |
25,009 | 2019-04-25 00:00:00 UTC | Health Care Sector Update for 04/25/2019: ABBV, BAX, BMY, JNJ, PFE, MRK, ABT, AMGN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-04-25-2019%3A-abbv-bax-bmy-jnj-pfe-mrk-abt-amgn-2019-04-25 | null | null | Top Health Care Stocks:
JNJ: Flat
PFE: -0.10%
ABT: Flat
MRK: +0.19%
AMGN: -0.67%
Pre-bell Thursday saw mixed health care majors.
In other sector news:
(+) AbbVie (ABBV) was advancing by more than 2% as it reported Q1 adjusted diluted earnings per share of $2.14, up from $1.87 during the year-ago quarter, and beating th... | In other sector news: (+) AbbVie (ABBV) was advancing by more than 2% as it reported Q1 adjusted diluted earnings per share of $2.14, up from $1.87 during the year-ago quarter, and beating the Capital IQ consensus forecast of $2.07. (-) Baxter International (BAX) was retreating more than 2% after it reported Q1 adjuste... | In other sector news: (+) AbbVie (ABBV) was advancing by more than 2% as it reported Q1 adjusted diluted earnings per share of $2.14, up from $1.87 during the year-ago quarter, and beating the Capital IQ consensus forecast of $2.07. Pre-bell Thursday saw mixed health care majors. (-) Baxter International (BAX) was retr... | In other sector news: (+) AbbVie (ABBV) was advancing by more than 2% as it reported Q1 adjusted diluted earnings per share of $2.14, up from $1.87 during the year-ago quarter, and beating the Capital IQ consensus forecast of $2.07. Top Health Care Stocks: JNJ: Flat (-) Baxter International (BAX) was retreating more th... | In other sector news: (+) AbbVie (ABBV) was advancing by more than 2% as it reported Q1 adjusted diluted earnings per share of $2.14, up from $1.87 during the year-ago quarter, and beating the Capital IQ consensus forecast of $2.07. Top Health Care Stocks: JNJ: Flat (-) Baxter International (BAX) was retreating more th... |
25,010 | 2019-04-23 00:00:00 UTC | Plaque Psoriasis Armamentarium Gets New Addition | ABBV | https://www.nasdaq.com/articles/plaque-psoriasis-armamentarium-gets-new-addition-2019-04-24 | null | null | (RTTNews) - The therapeutic armamentarium for plaque psoriasis patients is fairly well-stocked, and now there is one more addition to it.
The FDA has approved AbbVie's (ABBV) Skyrizi for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
What is plaqu... | The FDA has approved AbbVie's (ABBV) Skyrizi for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Skyrizi, whose generic name is Risankizumab-rzaa, is developed by AbbVie in collaboration with Boehringer Ingelheim. ABBV closed Tuesday's trading at $... | The FDA has approved AbbVie's (ABBV) Skyrizi for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Skyrizi, whose generic name is Risankizumab-rzaa, is developed by AbbVie in collaboration with Boehringer Ingelheim. ABBV closed Tuesday's trading at $... | The FDA has approved AbbVie's (ABBV) Skyrizi for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Skyrizi, whose generic name is Risankizumab-rzaa, is developed by AbbVie in collaboration with Boehringer Ingelheim. ABBV closed Tuesday's trading at $... | The FDA has approved AbbVie's (ABBV) Skyrizi for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Skyrizi, whose generic name is Risankizumab-rzaa, is developed by AbbVie in collaboration with Boehringer Ingelheim. ABBV closed Tuesday's trading at $... |
25,011 | 2019-04-22 00:00:00 UTC | Notable ETF Outflow Detected - IYH, ABBV, AMGN, MDT | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-iyh-abbv-amgn-mdt-2019-04-22 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $81.5 million dollar outflow -- that's a 3.8% decrease week over week (from 11,850,000 to 11,400,000). Among t... | Among the largest underlying components of IYH, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.5%, Amgen Inc (Symbol: AMGN) is off about 0.5%, and Medtronic PLC (Symbol: MDT) is lower by about 0.1%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price perform... | Among the largest underlying components of IYH, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.5%, Amgen Inc (Symbol: AMGN) is off about 0.5%, and Medtronic PLC (Symbol: MDT) is lower by about 0.1%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price perform... | Among the largest underlying components of IYH, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.5%, Amgen Inc (Symbol: AMGN) is off about 0.5%, and Medtronic PLC (Symbol: MDT) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, o... | Among the largest underlying components of IYH, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.5%, Amgen Inc (Symbol: AMGN) is off about 0.5%, and Medtronic PLC (Symbol: MDT) is lower by about 0.1%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price perform... |
25,012 | 2019-04-22 00:00:00 UTC | AbbVie Reports Its Q1 Results on Thursday: Here's What You Can Expect | ABBV | https://www.nasdaq.com/articles/abbvie-reports-its-q1-results-thursday-heres-what-you-can-expect-2019-04-22 | null | null | AbbVie (NYSE: ABBV) disappointed investors the last time when it reported its 2018 fourth-quarter in January. The big drugmaker missed Wall Street analysts' estimates on both the top and bottom lines.
The culprit? Worse than expected sales for Humira in the wake of biosimilar competition in Europe. AbbVie's share price... | Bill Chase, AbbVie's former CFO, who is retiring soon, stated in the company's Q4 conference call that international sales of Humira are expected to fall 30% in the full year 2019. AbbVie announced this decision in March, after a higher proportion of deaths was observed in patients taking Venclexta than in the control ... | The expectations game Wall Street analysts expect AbbVie to report Q1 revenue of $7.76 billion and adjusted earnings per share of $2.06. AbbVie (NYSE: ABBV) disappointed investors the last time when it reported its 2018 fourth-quarter in January. AbbVie's share price has floundered so far this year in large part becaus... | Bill Chase, AbbVie's former CFO, who is retiring soon, stated in the company's Q4 conference call that international sales of Humira are expected to fall 30% in the full year 2019. AbbVie expects 2019 full-year sales for the drug of $725 million. On the other hand, AbbVie is likely to report stronger sales for pancreat... | Mixed news for Humira As Humira goes, so goes AbbVie. Another strong quarter for hematology/oncology There should be plenty of good news for AbbVie's hematology/oncology franchise, which includes Imbruvica and Venclexta. AbbVie expects 2019 full-year sales for the drug of $725 million. |
25,013 | 2019-04-20 00:00:00 UTC | 3 Cancer Treatment Stocks to Buy in April | ABBV | https://www.nasdaq.com/articles/3-cancer-treatment-stocks-buy-april-2019-04-20 | null | null | Cancer drug sales are on track to eclipse the $200 billion mark early in the next decade, thanks to an innovation bonanza that's transformed oncology into the fastest-growing segment across the entire pharmaceutical industry. Specifically, a recent report by EvaluatePharma estimated that global cancer drug sales will r... | They picked Geron (NASDAQ: GERN), AbbVie (NYSE: ABBV), and Exelixis (NASDAQ: EXEL). A growing oncology franchise Keith Speights (AbbVie): Yes, AbbVie is best known for immunology rather than oncology. But AbbVie is steadily becoming a force to be reckoned with in cancer treatment. | See the 10 stocks *Stock Advisor returns as of March 1, 2019 George Budwell owns shares of AbbVie, Celgene, Geron, and Pfizer. They picked Geron (NASDAQ: GERN), AbbVie (NYSE: ABBV), and Exelixis (NASDAQ: EXEL). A growing oncology franchise Keith Speights (AbbVie): Yes, AbbVie is best known for immunology rather than on... | See the 10 stocks *Stock Advisor returns as of March 1, 2019 George Budwell owns shares of AbbVie, Celgene, Geron, and Pfizer. They picked Geron (NASDAQ: GERN), AbbVie (NYSE: ABBV), and Exelixis (NASDAQ: EXEL). A growing oncology franchise Keith Speights (AbbVie): Yes, AbbVie is best known for immunology rather than on... | They picked Geron (NASDAQ: GERN), AbbVie (NYSE: ABBV), and Exelixis (NASDAQ: EXEL). A growing oncology franchise Keith Speights (AbbVie): Yes, AbbVie is best known for immunology rather than oncology. But AbbVie is steadily becoming a force to be reckoned with in cancer treatment. |
25,014 | 2019-04-19 00:00:00 UTC | 5 Top Pharmaceutical Stocks to Buy in 2019 | ABBV | https://www.nasdaq.com/articles/5-top-pharmaceutical-stocks-buy-2019-2019-04-19 | null | null | More than $320 billion was spent on prescription drugs in the U.S. in 2016, a figure that's expected to nearly double to $610 billion by 2021, according to IQVIA (formerly QuintilesIMS).
With so much money being spent on necessary medicines, there's serious opportunity for pharmaceutical companies and investors alike. ... | AbbVie AbbVie's current products include three blockbuster drugs (i.e., drugs that generate annual sales of $1 billion or more). AbbVie's cancer drug Imbruvica and its hepatitis C drug Mavyret round out the company's list of current blockbusters. These and other products enabled AbbVie to make revenue of $32.8 billion ... | AbbVie AbbVie's current products include three blockbuster drugs (i.e., drugs that generate annual sales of $1 billion or more). AbbVie, Exelixis, Intercept, Pfizer, and Vertex certainly have risks, but they also provide investors a good chance of making solid returns over the long run. AbbVie's cancer drug Imbruvica a... | AbbVie AbbVie's current products include three blockbuster drugs (i.e., drugs that generate annual sales of $1 billion or more). AbbVie's cancer drug Imbruvica and its hepatitis C drug Mavyret round out the company's list of current blockbusters. These and other products enabled AbbVie to make revenue of $32.8 billion ... | AbbVie AbbVie's current products include three blockbuster drugs (i.e., drugs that generate annual sales of $1 billion or more). AbbVie's cancer drug Imbruvica and its hepatitis C drug Mavyret round out the company's list of current blockbusters. These and other products enabled AbbVie to make revenue of $32.8 billion ... |
25,015 | 2019-04-19 00:00:00 UTC | 5 Top Biotech Stocks to Buy in 2019 | ABBV | https://www.nasdaq.com/articles/5-top-biotech-stocks-buy-2019-2019-04-19 | null | null | Biotech stocks have delivered sizzling overall returns over the last few years. New drugs have improved the lives of patients and made big profits for investors in the process.
The future looks promising for biotech stocks as a group as well. Several currently successful drugs have room to increase sales. Even more pow... | AbbVie AbbVie's Humira is the best-selling drug in the world, having raked in a whopping $19.9 billion in 2018. In addition to these top-tier drugs, AbbVie also has several other products that generate significant revenue. Overall, AbbVie's revenue grew 16% year over year in 2018. | AbbVie AbbVie's Humira is the best-selling drug in the world, having raked in a whopping $19.9 billion in 2018. In addition to these top-tier drugs, AbbVie also has several other products that generate significant revenue. Overall, AbbVie's revenue grew 16% year over year in 2018. | AbbVie and Celgene appear likely to profit from their top blockbuster drugs for several more years as their other approved drugs and new drugs potentially on the way generate growth. AbbVie AbbVie's Humira is the best-selling drug in the world, having raked in a whopping $19.9 billion in 2018. In addition to these top-... | AbbVie AbbVie's Humira is the best-selling drug in the world, having raked in a whopping $19.9 billion in 2018. In addition to these top-tier drugs, AbbVie also has several other products that generate significant revenue. Overall, AbbVie's revenue grew 16% year over year in 2018. |
25,016 | 2019-04-16 00:00:00 UTC | Is TG Therapeutics a Buy? | ABBV | https://www.nasdaq.com/articles/tg-therapeutics-buy-2019-04-17 | null | null | TG Therapeutics (NASDAQ: TGTX), a clinical-stage hematology and autoimmune disease specialist, has been crushing the broader stock market this year. The biotech's shares surged higher in response to the news that the company's relapsed and refractory marginal zone lymphoma (MZL) candidate, umbralisib, may be up for an ... | After all, the biotech heavyweight AbbVie has placed a heavy emphasis on this particular space over the past few years with its development of both Imbruvica and Venclexta, and that could make it next to impossible for smaller companies like TG to carve out a profitable niche. The lowdown is that umbralisib seems to sp... | The lowdown is that umbralisib seems to sport a favorable efficacy and safety profile compared to other drugs in its class, as well as to its chief competitor in later-line MZL -- AbbVie's (NYSE: ABBV) Imbruvica. AbbVie, Gilead, Bristol-Myers Squibb/Celgene, Verastem, and others sport drugs that would compete directly ... | The lowdown is that umbralisib seems to sport a favorable efficacy and safety profile compared to other drugs in its class, as well as to its chief competitor in later-line MZL -- AbbVie's (NYSE: ABBV) Imbruvica. AbbVie, Gilead, Bristol-Myers Squibb/Celgene, Verastem, and others sport drugs that would compete directly ... | The lowdown is that umbralisib seems to sport a favorable efficacy and safety profile compared to other drugs in its class, as well as to its chief competitor in later-line MZL -- AbbVie's (NYSE: ABBV) Imbruvica. AbbVie, Gilead, Bristol-Myers Squibb/Celgene, Verastem, and others sport drugs that would compete directly ... |
25,017 | 2019-04-16 00:00:00 UTC | Is TG Therapeutics a Buy? | ABBV | https://www.nasdaq.com/articles/tg-therapeutics-buy-2019-04-16 | null | null | TG Therapeutics (NASDAQ: TGTX) , a clinical-stage hematology and autoimmune disease specialist, has been crushing the broader stock market this year. The biotech's shares surged higher in response to the news that the company's relapsed and refractory marginal zone lymphoma (MZL) candidate, umbralisib, may be up for an... | After all, the biotech heavyweight AbbVie has placed a heavy emphasis on this particular space over the past few years with its development of both Imbruvica and Venclexta, and that could make it next to impossible for smaller companies like TG to carve out a profitable niche. The lowdown is that umbralisib seems to sp... | The lowdown is that umbralisib seems to sport a favorable efficacy and safety profile compared to other drugs in its class, as well as to its chief competitor in later-line MZL -- AbbVie 's (NYSE: ABBV) Imbruvica. AbbVie, Gilead , Bristol-Myers Squibb/Celgene , Verastem , and others sport drugs that would compete direc... | The lowdown is that umbralisib seems to sport a favorable efficacy and safety profile compared to other drugs in its class, as well as to its chief competitor in later-line MZL -- AbbVie 's (NYSE: ABBV) Imbruvica. AbbVie, Gilead , Bristol-Myers Squibb/Celgene , Verastem , and others sport drugs that would compete direc... | The lowdown is that umbralisib seems to sport a favorable efficacy and safety profile compared to other drugs in its class, as well as to its chief competitor in later-line MZL -- AbbVie 's (NYSE: ABBV) Imbruvica. AbbVie, Gilead , Bristol-Myers Squibb/Celgene , Verastem , and others sport drugs that would compete direc... |
25,018 | 2019-04-16 00:00:00 UTC | J&J profit boosted by better-than-expected pharma unit sales | ABBV | https://www.nasdaq.com/articles/jj-profit-boosted-better-expected-pharma-unit-sales-2019-04-16 | null | null | By Manas Mishra and Saumya Joseph
April 16 () - Johnson & Johnson on Tuesday reported a first-quarter profit that exceeded Wall Street expectations on higher sales of its prescription medicines, including a double-digit increase for its psoriasis treatment Stelara, even as the company faces fierce competition for some ... | "We're really seeing the strength in pharma sales drive top and bottom line growth," said John Ham, associate advisor at New England Investment and Retirement Group, which owns J&J shares. The company on a conference call said 800 sites have already been certified to treat patients with its new nasal spray depression t... | But the company said it now sees the overall sales decline it expects due to competition from generics and biosimilars in 2019 coming in at the lower end of its prior $3 billion to $3.5 billion forecast. Overall sales increased slightly to $20.02 billion, topping analyst estimates of $19.61 billion. Sales from the medi... | By Manas Mishra and Saumya Joseph April 16 () - Johnson & Johnson on Tuesday reported a first-quarter profit that exceeded Wall Street expectations on higher sales of its prescription medicines, including a double-digit increase for its psoriasis treatment Stelara, even as the company faces fierce competition for some ... | But the company said it now sees the overall sales decline it expects due to competition from generics and biosimilars in 2019 coming in at the lower end of its prior $3 billion to $3.5 billion forecast. Overall sales increased slightly to $20.02 billion, topping analyst estimates of $19.61 billion. Sales from the medi... |
25,019 | 2019-04-15 00:00:00 UTC | ABBV May 31st Options Begin Trading | ABBV | https://www.nasdaq.com/articles/abbv-may-31st-options-begin-trading-2019-04-15 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the May 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 31st contracts and identified one put and one call contract of particular interest.
The put contract ... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $95.00 strike highlighted in red: Considering the fact that the $95.00 strike represents an approximate 17% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the poss... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $75.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $95.00 strike price has a current bid of 7 cents. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 31st contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $95.00 strike highlighted in red: Considering... |
25,020 | 2019-04-15 00:00:00 UTC | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-as-market-dips%3A-what-you-should-know-2019-04-15-0 | null | null | AbbVie (ABBV) closed the most recent trading day at $81.01, moving +0.28% from the previous trading session. This change outpaced the S&P 500's 0.06% loss on the day. Meanwhile, the Dow lost 0.1%, and the Nasdaq, a tech-heavy index, lost 0.1%.
Coming into today, shares of the drugmaker had gained 1.04% in the past mont... | AbbVie (ABBV) closed the most recent trading day at $81.01, moving +0.28% from the previous trading session. ABBV will be looking to display strength as it nears its nex t earnings release, which is expected to be April 25, 2019. In tha t report , analysts expect ABBV to post earnings of $2.05 per share. | AbbVie (ABBV) closed the most recent trading day at $81.01, moving +0.28% from the previous trading session. ABBV will be looking to display strength as it nears its nex t earnings release, which is expected to be April 25, 2019. In tha t report , analysts expect ABBV to post earnings of $2.05 per share. | AbbVie (ABBV) closed the most recent trading day at $81.01, moving +0.28% from the previous trading session. ABBV will be looking to display strength as it nears its nex t earnings release, which is expected to be April 25, 2019. In tha t report , analysts expect ABBV to post earnings of $2.05 per share. | ABBV currently has a Zacks Rank of #3 (Hold). AbbVie (ABBV) closed the most recent trading day at $81.01, moving +0.28% from the previous trading session. ABBV will be looking to display strength as it nears its nex t earnings release, which is expected to be April 25, 2019. |
25,021 | 2019-04-14 00:00:00 UTC | The Simple Way You Could Make 10% Each Year With AbbVie | ABBV | https://www.nasdaq.com/articles/simple-way-you-could-make-10-each-year-abbvie-2019-04-14 | null | null | AbbVie's (NYSE: ABBV) share price has grown by a compound annual growth rate (CAGR) of more than 15% since the company was spun off from Abbott Labs. But investors didn't see that kind of return in 2018, with AbbVie stock falling 5%. So far, AbbVie's performance this year has been even worse.
But there's a simple way t... | AbbVie's (NYSE: ABBV) share price has grown by a compound annual growth rate (CAGR) of more than 15% since the company was spun off from Abbott Labs. An added bonus I think that it's quite possible -- and even highly probable -- that investors who buy and hold AbbVie stock will be looking at a 10% dividend yield based ... | If AbbVie continued to raise its dividend by 15% each year, the dividend yield would double to 10% in less than five years. Even if AbbVie's share price only grows by 5% annually, the company's strong dividend combined with that relatively weak growth would give shareholders a total return of more than 10% -- without w... | If AbbVie continued to raise its dividend by 15% each year, the dividend yield would double to 10% in less than five years. Even if AbbVie only increases its dividend by 10% each year, you'd only have to wait seven years for the dividend to double and provide an annual return of 10% on your initial investment. An added... | Even if AbbVie only increases its dividend by 10% each year, you'd only have to wait seven years for the dividend to double and provide an annual return of 10% on your initial investment. Even better, AbbVie expects to generate $35 billion in sales from drugs other than Humira by 2025. Even if AbbVie's share price only... |
25,022 | 2019-04-12 00:00:00 UTC | ACWI, LLY, ABBV, ACN: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/acwi-lly-abbv-acn-etf-inflow-alert-2019-04-12 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI ETF (Symbol: ACWI) where we have detected an approximate $102.9 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 143,200,000 to 144... | Among the largest underlying components of ACWI, in trading today Lilly (Eli) & Co (Symbol: LLY) is down about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Accenture plc (Symbol: ACN) is higher by about 0.5%. For a complete list of holdings, visit the ACWI Holdings page » The chart below shows the one year pri... | Among the largest underlying components of ACWI, in trading today Lilly (Eli) & Co (Symbol: LLY) is down about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Accenture plc (Symbol: ACN) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF C... | Among the largest underlying components of ACWI, in trading today Lilly (Eli) & Co (Symbol: LLY) is down about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Accenture plc (Symbol: ACN) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF C... | Among the largest underlying components of ACWI, in trading today Lilly (Eli) & Co (Symbol: LLY) is down about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Accenture plc (Symbol: ACN) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF C... |
25,023 | 2019-04-12 00:00:00 UTC | Forward Guidance Will Make or Break JNJ Earnings | ABBV | https://www.nasdaq.com/articles/forward-guidance-will-make-or-break-jnj-earnings-2019-04-12 | null | null | Johnson & Johnson (NYSE:) announces earnings on Tuesday before market open. The New Brunswick, New Jersey-based healthcare company has become one of the strongest, longest-running brands in existence.
Source: Shutterstock
However, challenges with drug patent expirations have blunted earnings growth in JNJ stock. This h... | AbbVie (NYSE:) faces the same issue with Humira. Source: Shutterstock However, challenges with drug patent expirations have blunted earnings growth in JNJ stock. However, many often forget that medical devices and pharma each drive greater shares of the company’s revenue. | AbbVie (NYSE:) faces the same issue with Humira. Johnson & Johnson (NYSE:) announces earnings on Tuesday before market open. Source: Shutterstock However, challenges with drug patent expirations have blunted earnings growth in JNJ stock. | AbbVie (NYSE:) faces the same issue with Humira. Patent expirations have long affected pharma stocks, and this may have helped to trap JNJ stock in a range. JNJ Stock Retains Numerous Advantages Fortunately, some tailwinds could help JNJ stock. | AbbVie (NYSE:) faces the same issue with Humira. The company traditionally announces a hike to its JNJ stock dividend soon after the Q1 report. Concluding Thoughts on JNJ Stock Going into earnings, investors need to see guidance that will help break JNJ stock out of its range. |
25,024 | 2019-04-11 00:00:00 UTC | Notable Thursday Option Activity: ABBV, EBAY, CXO | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity-abbv-ebay-cxo-2019-04-11 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 71,116 contracts have traded so far, representing approximately 7.1 million underlying shares. That amounts to about 133.8% of ABBV's average daily trading volume over the ... | Especially high volume was seen for the $90 strike call option expiring April 12, 2019, with 26,101 contracts trading so far today, representing approximately 2.6 million underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol... | Especially high volume was seen for the $90 strike call option expiring April 12, 2019, with 26,101 contracts trading so far today, representing approximately 2.6 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $90 strike highlighted in orange: eBay Inc... | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 71,116 contracts have traded so far, representing approximately 7.1 million underlying shares. Especially high volume was seen for the $90 strike call option expiring April... | Especially high volume was seen for the $90 strike call option expiring April 12, 2019, with 26,101 contracts trading so far today, representing approximately 2.6 million underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol... |
25,025 | 2019-04-11 00:00:00 UTC | Notable Thursday Option Activity: ABBV, EBAY, CXO | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity-abbv-ebay-cxo-2019-04-11-0 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 71,116 contracts have traded so far, representing approximately 7.1 million underlying shares. That amounts to about 133.8% of ABBV's average daily trading volume over the ... | Especially high volume was seen for the $90 strike call option expiring April 12, 2019 , with 26,101 contracts trading so far today, representing approximately 2.6 million underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbo... | Especially high volume was seen for the $90 strike call option expiring April 12, 2019 , with 26,101 contracts trading so far today, representing approximately 2.6 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $90 strike highlighted in orange: eBay In... | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 71,116 contracts have traded so far, representing approximately 7.1 million underlying shares. Especially high volume was seen for the $90 strike call option expiring April... | Especially high volume was seen for the $90 strike call option expiring April 12, 2019 , with 26,101 contracts trading so far today, representing approximately 2.6 million underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbo... |
25,026 | 2019-04-10 00:00:00 UTC | Ex-Dividend Reminder: Becton, Dickinson, AbbVie and Abbott Laboratories | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder-becton-dickinson-abbvie-and-abbott-laboratories-2019-04-10 | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 4/12/19, Becton, Dickinson & Co (Symbol: BDXA), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co will pay its quarterly dividend of $0.7656 on 5/1... | If they do continue, the current estimated yields on annualized basis would be 4.93% for Becton, Dickinson & Co, 5.15% for AbbVie Inc, and 1.63% for Abbott Laboratories. Looking at the universe of stocks we cover at Dividend Channel, on 4/12/19, Becton, Dickinson & Co (Symbol: BDXA), AbbVie Inc (Symbol: ABBV), and Abbo... | Looking at the universe of stocks we cover at Dividend Channel, on 4/12/19, Becton, Dickinson & Co (Symbol: BDXA), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co will pay its quarterly dividend of $0.7656 on 5/1... | Looking at the universe of stocks we cover at Dividend Channel, on 4/12/19, Becton, Dickinson & Co (Symbol: BDXA), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co will pay its quarterly dividend of $0.7656 on 5/1... | If they do continue, the current estimated yields on annualized basis would be 4.93% for Becton, Dickinson & Co, 5.15% for AbbVie Inc, and 1.63% for Abbott Laboratories. Looking at the universe of stocks we cover at Dividend Channel, on 4/12/19, Becton, Dickinson & Co (Symbol: BDXA), AbbVie Inc (Symbol: ABBV), and Abbo... |
25,027 | 2019-04-08 00:00:00 UTC | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-outpaces-stock-market-gains%3A-what-you-should-know-2019-04-08-0 | null | null | AbbVie (ABBV) closed at $83.98 in the latest trading session, marking a +0.64% move from the prior day. This move outpaced the S&P 500's daily gain of 0.11%. Elsewhere, the Dow lost 0.32%, while the tech-heavy Nasdaq added 0.19%.
Coming into today, shares of the drugmaker had gained 6.66% in the past month. In that sam... | AbbVie (ABBV) closed at $83.98 in the latest trading session, marking a +0.64% move from the prior day. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $8.68 per share and revenue of $32.79 billion. ABBV will be looking to display strength as it nears its nex t earnings release, which is expected... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed at $83.98 in the latest trading session, marking a +0.64% move from the prior day. ABBV will be looking to display strength as it nears its nex t earnings release, which is exp... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $8.68 per share and revenue of $32.79 billion. AbbVie (ABBV) closed at $83.98 in the latest trading session, marking a +0.64% move from the prior day. ABBV will be looking to display strength as it nears its nex t earnings release, which is expected... | AbbVie (ABBV) closed at $83.98 in the latest trading session, marking a +0.64% move from the prior day. ABBV will be looking to display strength as it nears its nex t earnings release, which is expected to be April 25, 2019. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $8.68 per share and reve... |
25,028 | 2019-04-07 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-vs-johnson-johnson-2019-04-07 | null | null | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Both of these healthcare giants post consistent growth, crank out profits, and have a history of sharing the wealth with their investors.
But which is the better choic... | AbbVie has paid out a solid dividend ever since it was spun-off of its former parent company Abbott Laboratories (NYSE: ABT) back in 2013. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Growth You can't talk about A... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Winner: AbbVie Value AbbVie is currently trading for 22.5 times its trailing earnings, which isn't all that enticing of a price. Winner: AbbVie Income AbbVie and Johnso... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Winner: AbbVie Income AbbVie and Johnson & Johnson are both dividend dynamos. Winner: AbbVie The better buy There is a legitimate argument to be made that Johnson & Joh... | Winner: AbbVie The better buy There is a legitimate argument to be made that Johnson & Johnson's stock is the better choice right now since AbbVie's future is so heavily reliant on the success of Humira. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar h... |
25,029 | 2019-04-07 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-vs-johnson-johnson-2019-04-07-0 | null | null | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Both of these healthcare giants post consistent growth, crank out profits, and have a history of sharing the wealth with their investors.
But which is the better choice... | AbbVie has paid out a solid dividend ever since it was spun-off of its former parent company Abbott Laboratories (NYSE: ABT) back in 2013. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Growth You can't talk about A... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Winner: AbbVie Value AbbVie is currently trading for 22.5 times its trailing earnings, which isn't all that enticing of a price. Winner: AbbVie Income AbbVie and Johnso... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Winner: AbbVie Income AbbVie and Johnson & Johnson are both dividend dynamos. Winner: AbbVie The better buy There is a legitimate argument to be made that Johnson & Joh... | Winner: AbbVie The better buy There is a legitimate argument to be made that Johnson & Johnson's stock is the better choice right now since AbbVie's future is so heavily reliant on the success of Humira. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar h... |
25,030 | 2019-04-04 00:00:00 UTC | 10 Medical Marijuana Stocks to Cure Your Portfolio | ABBV | https://www.nasdaq.com/articles/10-medical-marijuana-stocks-to-cure-your-portfolio-2019-04-04 | null | null | Invariably, no other investment class generates as much interest and controversy as marijuana stocks. Within a generation, toward legalization shifted dramatically from strongly opposed to mostly supportive. This is largely due to demographics, as the more progressive millennials replace older Americans in positions of... | Here are 10 names to consider: Medical Marijuana Stocks: AbbVie (ABBV) Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Still, Ab... | Here are 10 names to consider: Medical Marijuana Stocks: AbbVie (ABBV) Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Still, Ab... | Here are 10 names to consider: Medical Marijuana Stocks: AbbVie (ABBV) Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Still, Ab... | Here are 10 names to consider: Medical Marijuana Stocks: AbbVie (ABBV) Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:) isn’t the first name you think about. One of the healthcare sector’s blue chips, ABBV stock has soared on its vast therapeutic pipeline. Still, Ab... |
25,031 | 2019-04-04 00:00:00 UTC | Novartis Resubmits BLA to FDA for Biosimilar of Neulasta | ABBV | https://www.nasdaq.com/articles/novartis-resubmits-bla-to-fda-for-biosimilar-of-neulasta-2019-04-04-0 | null | null | Novartis AG'sNVS generic arm, Sandoz, resubmitted its Biologics License Application (BLA) for a proposed biosimilar of Neulasta to the FDA.
The BLA was resubmitted to the FDA to address the issues mentioned in the complete response letter (CRL) received in June 2016. The resubmission includes new data from a pivotal ph... | However, Novartis cannot launch Hyrimoz in the United States until October 2023, per a settlement with AbbVie, Inc. ABBV . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Amgen Inc. (AMGN): F... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. However, Novartis cannot launch Hyrimoz in the Unit... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. However, Novartis cannot launch Hyrimoz in the Unit... | However, Novartis cannot launch Hyrimoz in the United States until October 2023, per a settlement with AbbVie, Inc. ABBV . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Amgen Inc. (AMGN): F... |
25,032 | 2019-04-03 00:00:00 UTC | Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003 | ABBV | https://www.nasdaq.com/articles/alector-alec-initiates-phase-i-alzheimers-study-on-al003-2019-04-03-0 | null | null | Alector, Inc.ALEC announced the initiation of the phase I INTERCEPT study on AL003 for the treatment of Alzheimer's disease. The randomized, double-blind, placebo-controlled, dose escalation study will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of AL003 in healthy volunt... | AL003 is the company's second product candidate being developed for the treatment of patients with Alzheimer's disease in collaboration with AbbVie ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AC Immune SA (ACIU): Free Stock ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AC Immune SA (ACIU): Free Stock Analysis Report ALECTOR INC (ALEC): Free Stock Analysis Report To read this article on Zacks.com click here. AL003 is the company's second product candidat... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AC Immune SA (ACIU): Free Stock Analysis Report ALECTOR INC (ALEC): Free Stock Analysis Report To read this article on Zacks.com click here. AL003 is the company's second product candidat... | AL003 is the company's second product candidate being developed for the treatment of patients with Alzheimer's disease in collaboration with AbbVie ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AC Immune SA (ACIU): Free Stock ... |
25,033 | 2019-04-03 00:00:00 UTC | 10 Best Selling Drugs Of 2018 | ABBV | https://www.nasdaq.com/articles/10-best-selling-drugs-2018-2019-04-03 | null | null | (RTTNews) - It typically takes 10-12 years to introduce a new drug into the market - i.e., from the initial discovery stage to regulatory approval - and it costs the drugmakers an average of $2.6 billion.
The rising prescription drug prices are posing a huge problem for the healthcare system in the United States. On av... | (RTTNews) - It typically takes 10-12 years to introduce a new drug into the market - i.e., from the initial discovery stage to regulatory approval - and it costs the drugmakers an average of $2.6 billion. Early this year, the Health and Human Services Secretary Alex Azar and Inspector General Daniel Levinson proposed a... | The rising prescription drug prices are posing a huge problem for the healthcare system in the United States. Despite the Trump administration taking steps to curb the rising drug prices, the drugmakers continue to ratchet up the prices. The drug companies may hike their drugs' prices due to various factors like shorta... | Unlike other countries, the U.S. allows manufacturers of pharmaceutical drugs to set their own prices for the drugs they develop. Early this year, the Health and Human Services Secretary Alex Azar and Inspector General Daniel Levinson proposed a rule to lower prescription drug prices and out-of-pocket costs by encourag... | On average, an American spends about $1,200 on prescription drugs a year, according to a report by the Organization for Economic Cooperation and Development. In a list of top 20 expensive prescription drugs in the U.S., compiled by GoodRx, a medical app, which helps find the lowest cost pharmacy for prescriptions, Acti... |
25,034 | 2019-04-03 00:00:00 UTC | Notable ETF Outflow Detected - IWV, ABBV, MMM, HON | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-iwv-abbv-mmm-hon-2019-04-03 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $269.8 million dollar outflow -- that's a 2.8% decrease week over week (from 57,850,000 to 56,250,000). Among the... | Among the largest underlying components of IWV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, 3M Co (Symbol: MMM) is up about 0.4%, and Honeywell International Inc (Symbol: HON) is lower by about 0.3%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price... | Among the largest underlying components of IWV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, 3M Co (Symbol: MMM) is up about 0.4%, and Honeywell International Inc (Symbol: HON) is lower by about 0.3%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price... | Among the largest underlying components of IWV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, 3M Co (Symbol: MMM) is up about 0.4%, and Honeywell International Inc (Symbol: HON) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... | Among the largest underlying components of IWV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, 3M Co (Symbol: MMM) is up about 0.4%, and Honeywell International Inc (Symbol: HON) is lower by about 0.3%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price... |
25,035 | 2019-04-02 00:00:00 UTC | Noteworthy Tuesday Option Activity: MO, RTN, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-mo-rtn-abbv-2019-04-02 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Altria Group Inc (Symbol: MO), where a total of 56,041 contracts have traded so far, representing approximately 5.6 million underlying shares. That amounts to about 46% of MO's average daily trading volume over ... | Particularly high volume was seen for the $100 strike call option expiring June 21, 2019, with 4,217 contracts trading so far today, representing approximately 421,700 underlying shares of ABBV. Below is a chart showing RTN's trailing twelve month trading history, with the $185 strike highlighted in orange: And AbbVie ... | Below is a chart showing RTN's trailing twelve month trading history, with the $185 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 26,596 contracts, representing approximately 2.7 million underlying shares or approximately 44.9% of ABBV's average daily trading volume over the ... | Below is a chart showing RTN's trailing twelve month trading history, with the $185 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 26,596 contracts, representing approximately 2.7 million underlying shares or approximately 44.9% of ABBV's average daily trading volume over the ... | Below is a chart showing RTN's trailing twelve month trading history, with the $185 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 26,596 contracts, representing approximately 2.7 million underlying shares or approximately 44.9% of ABBV's average daily trading volume over the ... |
25,036 | 2019-04-02 00:00:00 UTC | Noteworthy Tuesday Option Activity: MO, RTN, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-mo-rtn-abbv-2019-04-02-0 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Altria Group Inc (Symbol: MO), where a total of 56,041 contracts have traded so far, representing approximately 5.6 million underlying shares. That amounts to about 46% of MO's average daily trading volume over ... | Particularly high volume was seen for the $100 strike call option expiring June 21, 2019 , with 4,217 contracts trading so far today, representing approximately 421,700 underlying shares of ABBV. Below is a chart showing RTN's trailing twelve month trading history, with the $185 strike highlighted in orange: And AbbVie... | Below is a chart showing RTN's trailing twelve month trading history, with the $185 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 26,596 contracts, representing approximately 2.7 million underlying shares or approximately 44.9% of ABBV's average daily trading volume over the ... | Below is a chart showing RTN's trailing twelve month trading history, with the $185 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 26,596 contracts, representing approximately 2.7 million underlying shares or approximately 44.9% of ABBV's average daily trading volume over the ... | Below is a chart showing RTN's trailing twelve month trading history, with the $185 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 26,596 contracts, representing approximately 2.7 million underlying shares or approximately 44.9% of ABBV's average daily trading volume over the ... |
25,037 | 2019-04-01 00:00:00 UTC | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-but-lags-market%3A-what-you-should-know-2019-04-01-0 | null | null | In the latest trading session, AbbVie (ABBV) closed at $80.76, marking a +0.2% move from the previous day. This change lagged the S&P 500's 1.16% gain on the day. Meanwhile, the Dow gained 1.27%, and the Nasdaq, a tech-heavy index, added 1.29%.
Heading into today, shares of the drugmaker had gained 1.7% over the past m... | In the latest trading session, AbbVie (ABBV) closed at $80.76, marking a +0.2% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its nex t earnings release. In tha t report , analysts expect ABBV to post earnings of $2.05 per share. | In the latest trading session, AbbVie (ABBV) closed at $80.76, marking a +0.2% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its nex t earnings release. In tha t report , analysts expect ABBV to post earnings of $2.05 per share. | In the latest trading session, AbbVie (ABBV) closed at $80.76, marking a +0.2% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its nex t earnings release. In tha t report , analysts expect ABBV to post earnings of $2.05 per share. | In the latest trading session, AbbVie (ABBV) closed at $80.76, marking a +0.2% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its nex t earnings release. In tha t report , analysts expect ABBV to post earnings of $2.05 per share. |
25,038 | 2019-03-31 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-vs-johnson-johnson-2019-03-31 | null | null | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) together market one of the top cancer drugs in the world, Imbruvica. But while the two companies are partners in one area, they compete on other fronts, particularly in immunology.
J&J has been the bigger winner in terms of stock performance over the last 12 months,... | J&J has been the bigger winner in terms of stock performance over the last 12 months, rising around 9%, with AbbVie's share price dropping 15% during the period. Biosimilar rivals won't be available in the U.S. until 2023, giving AbbVie several more years of huge sales from its top drug. AbbVie (NYSE: ABBV) and Johnson... | The case for AbbVie Many investors have been leery of AbbVie because the company's top-selling drug, Humira, now faces biosimilar competition in Europe. Overall, the drugmaker expects $35 billion in incremental risk-adjusted sales from drugs other than Humira by 2025 -- more than AbbVie made in total last year with Hum... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) together market one of the top cancer drugs in the world, Imbruvica. The case for AbbVie Many investors have been leery of AbbVie because the company's top-selling drug, Humira, now faces biosimilar competition in Europe. Overall, the drugmaker expects $35 billion i... | Overall, the drugmaker expects $35 billion in incremental risk-adjusted sales from drugs other than Humira by 2025 -- more than AbbVie made in total last year with Humira included. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) together market one of the top cancer drugs in the world, Imbruvica. J&J has been the... |
25,039 | 2019-03-26 00:00:00 UTC | AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan | ABBV | https://www.nasdaq.com/articles/abbvies-psoriasis-drug-skyrizi-gets-first-approval-in-japan-2019-03-26 | null | null | AbbVie Inc.ABBV announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved its key pipeline candidate, risankizumab, for the treatment of adult patients with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis. The interleukin-23 (IL-23) inhibito... | The nod and the successful commercialization of upadacitinib are crucial for long-term growth at AbbVie, especially as a biosimilar competition looms large on its blockbuster RA drug, Humira. AbbVie Inc.ABBV announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved its key pipeline candidat... | AbbVie Inc.ABBV announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved its key pipeline candidate, risankizumab, for the treatment of adult patients with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis. Click to get this free report Pfize... | AbbVie Inc.ABBV announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved its key pipeline candidate, risankizumab, for the treatment of adult patients with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis. Also, a global phase II study evalu... | Also, a global phase II study evaluated Skyrizi for treating patients with active psoriatic arthritis, which also formed basis of its application filing in Japan AbbVie has developed Skyrizi in collaboration with the privately held Boehringer Ingelheim. With Humira accounting for around 61% of AbbVie's sales, the entry... |
25,040 | 2019-03-26 00:00:00 UTC | Health Care Select Sector SPDR Fund Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-inflow-2019-03-26 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $298.9 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 209,... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Lilly (Eli) & Co (Symbol: LLY) is up about 1.3%, and Danaher Corp (Symbol: DHR) is up by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , o... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Lilly (Eli) & Co (Symbol: LLY) is up about 1.3%, and Danaher Corp (Symbol: DHR) is up by about 1.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performa... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Lilly (Eli) & Co (Symbol: LLY) is up about 1.3%, and Danaher Corp (Symbol: DHR) is up by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , o... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Lilly (Eli) & Co (Symbol: LLY) is up about 1.3%, and Danaher Corp (Symbol: DHR) is up by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , o... |
25,041 | 2019-03-25 00:00:00 UTC | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-dips-more-than-broader-markets%3A-what-you-should-know-2019-03-25 | null | null | In the latest trading session, AbbVie (ABBV) closed at $79.64, marking a -0.15% move from the previous day. This change lagged the S&P 500's 0.08% loss on the day. Elsewhere, the Dow gained 0.06%, while the tech-heavy Nasdaq lost 0.07%.
Prior to today's trading, shares of the drugmaker had gained 1.28% over the past mo... | In the latest trading session, AbbVie (ABBV) closed at $79.64, marking a -0.15% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its nex t earnings report date. On that day, ABBV is projected to report earnings of $2.05 per share, which would represent year-over-year gro... | In the latest trading session, AbbVie (ABBV) closed at $79.64, marking a -0.15% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its nex t earnings report date. On that day, ABBV is projected to report earnings of $2.05 per share, which would represent year-over-year gro... | In the latest trading session, AbbVie (ABBV) closed at $79.64, marking a -0.15% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its nex t earnings report date. On that day, ABBV is projected to report earnings of $2.05 per share, which would represent year-over-year gro... | In the latest trading session, AbbVie (ABBV) closed at $79.64, marking a -0.15% move from the previous day. ABBV currently has a Zacks Rank of #3 (Hold). Wall Street will be looking for positivity from ABBV as it approaches its nex t earnings report date. |
25,042 | 2019-03-24 00:00:00 UTC | 4 Blockbuster Drug Launches to Watch in 2019 | ABBV | https://www.nasdaq.com/articles/4-blockbuster-drug-launches-watch-2019-2019-03-24 | null | null | Get ready for some blockbuster drug launches that could get intense.
Clarivate Analytics has offered a report on experimental drugs entering the market soon that are expected to generate sales above $1 billion in 2023. Every potential blockbuster is important to the company that launches it, but there are a few in the ... | In 2019, AbbVie (NYSE: ABBV) , Alexion Pharmaceuticals (NASDAQ: ALXN) , and Aimmune Therapeutics (NASDAQ: AIMT) face upcoming drug launches that they can't afford to fumble. Upadacitinib: Another rheumatoid arthritis treatment AbbVie's mega-blockbuster rheumatoid arthritis injection, Humira, is losing ground to biosimi... | In 2019, AbbVie (NYSE: ABBV) , Alexion Pharmaceuticals (NASDAQ: ALXN) , and Aimmune Therapeutics (NASDAQ: AIMT) face upcoming drug launches that they can't afford to fumble. Upadacitinib: Another rheumatoid arthritis treatment AbbVie's mega-blockbuster rheumatoid arthritis injection, Humira, is losing ground to biosimi... | In 2019, AbbVie (NYSE: ABBV) , Alexion Pharmaceuticals (NASDAQ: ALXN) , and Aimmune Therapeutics (NASDAQ: AIMT) face upcoming drug launches that they can't afford to fumble. AbbVie and Alexion have all the resources necessary to launch a new drug, while Aimmune will need to build a new sales team to market AR101. Upada... | Skyrizi: Another psoriasis drug Skyrizi will be the brand name for risankizumab, a potential new psoriasis injection also from AbbVie. In 2019, AbbVie (NYSE: ABBV) , Alexion Pharmaceuticals (NASDAQ: ALXN) , and Aimmune Therapeutics (NASDAQ: AIMT) face upcoming drug launches that they can't afford to fumble. Upadacitini... |
25,043 | 2019-03-24 00:00:00 UTC | 3 Bargain Stocks You Can Buy Today | ABBV | https://www.nasdaq.com/articles/3-bargain-stocks-you-can-buy-today-2019-03-24 | null | null | Most longtime investors would tell you that the stock market is anything but cheap right now. That's to be expected after a bull market that's now gone on 10 years and counting.
But there are still some bargains to be found. Three stocks that appear to be quite attractively priced are AbbVie (NYSE: ABBV) , Celgene (NAS... | The stock is priced at a discount primarily because of concerns that over 60% of AbbVie's total revenue comes from one drug, Humira, that now faces biosimilar competition in Europe. Three stocks that appear to be quite attractively priced are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and DaVita (NYSE: DVA) . AbbVi... | Three stocks that appear to be quite attractively priced are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and DaVita (NYSE: DVA) . AbbVie Big drugmaker AbbVie's shares trade at less than nine times expected earnings. The stock is priced at a discount primarily because of concerns that over 60% of AbbVie's total reven... | Three stocks that appear to be quite attractively priced are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and DaVita (NYSE: DVA) . Celgene Celgene's valuation is even more attractive than AbbVie's, with the biotech's shares trading at a little over seven times expected earnings. See the 10 stocks *Stock Advisor retur... | Celgene Celgene's valuation is even more attractive than AbbVie's, with the biotech's shares trading at a little over seven times expected earnings. Three stocks that appear to be quite attractively priced are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and DaVita (NYSE: DVA) . AbbVie Big drugmaker AbbVie's shares t... |
25,044 | 2019-03-24 00:00:00 UTC | Where Will AbbVie Be in 10 Years? | ABBV | https://www.nasdaq.com/articles/where-will-abbvie-be-10-years-2019-03-24 | null | null | Warren Buffett once said, "If you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes." He was exactly right. And as a result, it makes sense to think about what the stocks you buy might look like 10 years from now.
My favorite big pharma stock is AbbVie (NYSE: ABBV) . I have pou... | Venclexta is likely to also be a powerhouse for AbbVie as it picks up additional approvals in multiple myeloma and as a first-line treatment for chronic lymphocytic leukemia (CLL). While Imbruvica and Venclexta are on track to be even bigger winners in treating various blood cancers, I think that AbbVie will gain some ... | Rova-T was admittedly a big disappointment , but AbbVie's pipeline includes several promising phase 1 drugs that target solid tumors. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. My favorite big pharma stock is AbbVie (NYSE: ABBV) ... | Humira in the rearview mirror (sort of) Most of the worries about AbbVie right now center on the company's reliance on immunology drug Humira. A dividend king By virtue of its lineage as part of Abbott Labs , AbbVie belongs to the exclusive club of Dividend Aristocrats -- S&P 500 companies that have increased their div... | Where will AbbVie be in 10 years? My favorite big pharma stock is AbbVie (NYSE: ABBV) . I have pounded the table on why AbbVie is a great pick for growth investors, income investors, and value investors. |
25,045 | 2019-03-22 00:00:00 UTC | This is Why AbbVie (ABBV) is a Great Dividend Stock | ABBV | https://www.nasdaq.com/articles/this-is-why-abbvie-abbv-is-a-great-dividend-stock-2019-03-22 | null | null | All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
While cash flow can come from bond interest or interest fro... | AbbVie in Focus AbbVie (ABBV) is headquartered in North Chicago, and is in the Medical sector. In the past five-year period, AbbVie has increased its dividend 5 times on a year-over-year basis for an average annual increase of 18.92%. AbbVie's current payout ratio is 49%, meaning it paid out 49% of its trailing 12-mont... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie in Focus AbbVie (ABBV) is headquartered in North Chicago, and is in the Medical sector. In the past five-year period, AbbVie has increased its dividend 5 times on a year-over-year basis for ... | AbbVie in Focus AbbVie (ABBV) is headquartered in North Chicago, and is in the Medical sector. In the past five-year period, AbbVie has increased its dividend 5 times on a year-over-year basis for an average annual increase of 18.92%. AbbVie's current payout ratio is 49%, meaning it paid out 49% of its trailing 12-mont... | AbbVie in Focus AbbVie (ABBV) is headquartered in North Chicago, and is in the Medical sector. In the past five-year period, AbbVie has increased its dividend 5 times on a year-over-year basis for an average annual increase of 18.92%. AbbVie's current payout ratio is 49%, meaning it paid out 49% of its trailing 12-mont... |
25,046 | 2019-03-21 00:00:00 UTC | Does Recent AbbVie Stock Weakness Make It A Buy? 3 Pros, 3 Cons | ABBV | https://www.nasdaq.com/articles/does-recent-abbvie-stock-weakness-make-it-buy-3-pros-3-cons-2019-03-21 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie (NYSE: ABBV ) stock continues to slide, despite a buoyant market. The shares are down 12.3% year-to-date and 28.5% over the past 12 months. That's a dreadful performance in comparison to either the Nasdaq Composite index 's 5.22% increase or the 11.8... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE: ABBV ) stock continues to slide, despite a buoyant market. ABBV stock makes up 5% of the pharma industry exchange-traded fund's current portfolio. Losses continued following AbbVie's latest quarterly report. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE: ABBV ) stock continues to slide, despite a buoyant market. At that point, AbbVie could lose the biggest share of its revenue if other pipeline drugs don't come along fast enough. AbbVie Stock Pros That Dividend Yield : Just as any bearish argu... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE: ABBV ) stock continues to slide, despite a buoyant market. AbbVie Stock Pros That Dividend Yield : Just as any bearish argument involving ABBV stock starts with Humira's patent problems, bulls invariably point to the dividend yield. More From ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE: ABBV ) stock continues to slide, despite a buoyant market. AbbVie Stock Cons Replacing Humira: Investors are asking where AbbVie goes after Humira? ABBV stock makes up 5% of the pharma industry exchange-traded fund's current portfolio. |
25,047 | 2019-03-20 00:00:00 UTC | AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA | ABBV | https://www.nasdaq.com/articles/abbvies-venclexta-multiple-myeloma-studies-put-on-hold-by-fda-2019-03-20 | null | null | AbbVie, Inc.ABBV announced that the FDA has placed a partial clinical hold on all studies evaluating its leukemia drug, Venclexta (venetoclax) for the treatment of multiple myeloma. The decision was taken after, in the ongoing phase III BELLINI study, a higher proportion of deaths were observed in the Venclexta arm com... | AbbVie, Inc.ABBV announced that the FDA has placed a partial clinical hold on all studies evaluating its leukemia drug, Venclexta (venetoclax) for the treatment of multiple myeloma. AbbVie's stock has declined 12.3% this year so far against an increase of 3.7% recorded by the industry . Venclexta is jointly marketed by... | AbbVie, Inc.ABBV announced that the FDA has placed a partial clinical hold on all studies evaluating its leukemia drug, Venclexta (venetoclax) for the treatment of multiple myeloma. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson ... | AbbVie, Inc.ABBV announced that the FDA has placed a partial clinical hold on all studies evaluating its leukemia drug, Venclexta (venetoclax) for the treatment of multiple myeloma. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson ... | AbbVie, Inc.ABBV announced that the FDA has placed a partial clinical hold on all studies evaluating its leukemia drug, Venclexta (venetoclax) for the treatment of multiple myeloma. AbbVie's stock has declined 12.3% this year so far against an increase of 3.7% recorded by the industry . Venclexta is jointly marketed by... |
25,048 | 2019-03-19 00:00:00 UTC | Why You Should Buy ABBV Stock for Income and Value | ABBV | https://www.nasdaq.com/articles/why-you-should-buy-abbv-stock-income-and-value-2019-03-19 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Today, I'd like to discuss the outlook for AbbVie (NYSE: ABBV ), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been hammered following its earning report of Jan. 25.
Source: ... | A Hiccup in the Robust Fundamental Story In 2013, Abbott Laboratories (NYSE: ABT ) spun off its research-based pharmaceuticals business, creating AbbVie, an independent biopharmaceutical company. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, I'd like to discuss the outlook for AbbVie (NYSE: ABBV... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, I'd like to discuss the outlook for AbbVie (NYSE: ABBV ), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been hammered following its earning report of Jan. 25. A Hiccup... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, I'd like to discuss the outlook for AbbVie (NYSE: ABBV ), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been hammered following its earning report of Jan. 25. The Bott... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, I'd like to discuss the outlook for AbbVie (NYSE: ABBV ), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been hammered following its earning report of Jan. 25. The Bott... |
25,049 | 2019-03-19 00:00:00 UTC | FDA puts partial hold on clinical trials of AbbVie's cancer drug | ABBV | https://www.nasdaq.com/articles/fda-puts-partial-hold-clinical-trials-abbvies-cancer-drug-2019-03-19 | null | null | March 19 () - AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study.
Data review from the trial showed a high... | March 19 () - AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study. However, the clinical hold does not impa... | March 19 () - AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study. However, the clinical hold does not impa... | March 19 () - AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study. However, the clinical hold does not impa... | March 19 () - AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study. It brought in $344 million revenue for A... |
25,050 | 2019-03-18 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-2019-03-18 | null | null | AbbVie (ABBV) closed the most recent trading day at $80.65, moving -0.85% from the previous trading session. This move lagged the S&P 500's daily gain of 0.37%. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.34%.
Coming into today, shares of the drugmaker had gained 1.02% in the past month. I... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $8.68 per share and revenue of $32.79 billion. AbbVie (ABBV) closed the most recent trading day at $80.65, moving -0.85% from the previous trading session. ABBV will be looking to display strength as it nears its nex t earnings release. | AbbVie (ABBV) closed the most recent trading day at $80.65, moving -0.85% from the previous trading session. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. ABBV will be looking to display strength as it nears its nex t earnings release. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $8.68 per share and revenue of $32.79 billion. AbbVie (ABBV) closed the most recent trading day at $80.65, moving -0.85% from the previous trading session. ABBV will be looking to display strength as it nears its nex t earnings release. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $8.68 per share and revenue of $32.79 billion. Any recent changes to analyst estimates for ABBV should also be noted by investors. AbbVie (ABBV) closed the most recent trading day at $80.65, moving -0.85% from the previous trading session. |
25,051 | 2019-03-17 00:00:00 UTC | 2 Things Investors Are Missing About AbbVie | ABBV | https://www.nasdaq.com/articles/2-things-investors-are-missing-about-abbvie-2019-03-17 | null | null | AbbVie (NYSE: ABBV) has seen better days. After a 54% gain in 2017, the big-pharma stock lost ground last year. So far in 2019, AbbVie's share price has fallen by a double-digit percentage.
Are investors missing something about AbbVie? The company's president, Michael Severino, thinks so. He fielded questions at the Co... | AbbVie has drugs in phase 2 testing that target treatment of Alzheimer's disease, multiple sclerosis, and progressive supranuclear palsy (PSP). AbbVie (NYSE: ABBV) has seen better days. So far in 2019, AbbVie's share price has fallen by a double-digit percentage. | The overall strength of AbbVie's business Severino quickly pointed out that AbbVie's business remains very strong overall. AbbVie has drugs in phase 2 testing that target treatment of Alzheimer's disease, multiple sclerosis, and progressive supranuclear palsy (PSP). AbbVie (NYSE: ABBV) has seen better days. | The overall strength of AbbVie's business Severino quickly pointed out that AbbVie's business remains very strong overall. The strength of AbbVie's earlier-stage pipeline AbbVie's late-stage pipeline deservedly gets the most attention with the blockbuster potential for risankizumab and upadacitinib. Another thing you d... | AbbVie isn't viewed as a leader in neuroscience, although it does have one approved product in the category with Parkinson's disease drug Duodopa. AbbVie (NYSE: ABBV) has seen better days. So far in 2019, AbbVie's share price has fallen by a double-digit percentage. |
25,052 | 2019-03-15 00:00:00 UTC | IWV, UNH, ABBV, HON: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/iwv-unh-abbv-hon-large-inflows-detected-etf-2019-03-15 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $66.4 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 58,600,000 to 59... | Among the largest underlying components of IWV, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.6%, AbbVie Inc (Symbol: ABBV) is down about 0.7%, and Honeywell International Inc (Symbol: HON) is relatively unchanged. For a complete list of holdings, visit the IWV Holdings page » The chart below sho... | Among the largest underlying components of IWV, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.6%, AbbVie Inc (Symbol: ABBV) is down about 0.7%, and Honeywell International Inc (Symbol: HON) is relatively unchanged. For a complete list of holdings, visit the IWV Holdings page » The chart below sho... | Among the largest underlying components of IWV, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.6%, AbbVie Inc (Symbol: ABBV) is down about 0.7%, and Honeywell International Inc (Symbol: HON) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of E... | Among the largest underlying components of IWV, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.6%, AbbVie Inc (Symbol: ABBV) is down about 0.7%, and Honeywell International Inc (Symbol: HON) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of E... |
25,053 | 2019-03-14 00:00:00 UTC | 3 Dividend Aristocrats to Buy and Hold Forever | ABBV | https://www.nasdaq.com/articles/3-dividend-aristocrats-buy-and-hold-forever-2019-03-14 | null | null | Dividend Aristocrats -- or companies that have raised their dividends for a minimum of 25 consecutive years -- are always worth considering as long-term investing vehicles. These elite income stocks, after all, have trounced the performance of the broader markets for nearly 30 straight years at this point.
We thus aske... | They choose AbbVie (NYSE: ABBV) , PepsiCo (NASDAQ: PEP) , and McDonald's (NYSE: MCD) . A perfect buying opportunity George Budwell (AbbVie): AbbVie, an Illinois-based drugmaker, is a Dividend Aristocrat by virtue of its former parent company, Abbott Laboratories . Since going public in 2013, for instance, AbbVie has ra... | A perfect buying opportunity George Budwell (AbbVie): AbbVie, an Illinois-based drugmaker, is a Dividend Aristocrat by virtue of its former parent company, Abbott Laboratories . They choose AbbVie (NYSE: ABBV) , PepsiCo (NASDAQ: PEP) , and McDonald's (NYSE: MCD) . Since going public in 2013, for instance, AbbVie has ra... | A perfect buying opportunity George Budwell (AbbVie): AbbVie, an Illinois-based drugmaker, is a Dividend Aristocrat by virtue of its former parent company, Abbott Laboratories . Despite its top-notch dividend growth rate and its industry-leading levels of revenue growth over the past five years, AbbVie's stock has fall... | They choose AbbVie (NYSE: ABBV) , PepsiCo (NASDAQ: PEP) , and McDonald's (NYSE: MCD) . A perfect buying opportunity George Budwell (AbbVie): AbbVie, an Illinois-based drugmaker, is a Dividend Aristocrat by virtue of its former parent company, Abbott Laboratories . Since going public in 2013, for instance, AbbVie has ra... |
25,054 | 2019-03-13 00:00:00 UTC | Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study | ABBV | https://www.nasdaq.com/articles/theravance-tbph-starts-dosing-in-ulcerative-colitis-study-2019-03-13 | null | null | Theravance Biopharma, Inc.TBPH has dosed the first patient in a phase IIb/III study on its gut-selective pan-Janus kinase (JAK) inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis. TD-1473 is currently being developed in collaboration with Janssen, a subsidiary of Johnson & Johnson JNJ ... | Some marketed ulcerative colitis treatments include Pfizer's PFE JAK inhibitor, Xeljanz and AbbVie's ABBV Humira. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Theravance Biopharma, Inc. (TBP... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Theravance Biopharma, Inc. (TBPH): Free Stock Analysis Report To read this article on Zacks.com click here. Some marketed ulcerative colitis trea... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Theravance Biopharma, Inc. (TBPH): Free Stock Analysis Report To read this article on Zacks.com click here. Some marketed ulcerative colitis trea... | Some marketed ulcerative colitis treatments include Pfizer's PFE JAK inhibitor, Xeljanz and AbbVie's ABBV Humira. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Theravance Biopharma, Inc. (TBP... |
25,055 | 2019-03-12 00:00:00 UTC | Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval | ABBV | https://www.nasdaq.com/articles/pfizers-herceptin-biosimilar-trazimera-gets-fda-approval-2019-03-12 | null | null | Pfizer, Inc. PFE announced FDA approval of Trazimera, a biosimilar version Roche's RHHBY breast cancer drug, Herceptin.
Trazimera is approved for the treatment of HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric cancer. We remind investors that in April last year, the FDA had given a complet... | With a biosimilar version of AbbVie's ABBV Humira also under review in the United States, Pfizer expects potential U.S. approvals for up to four biosimilar products in 2019. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. With a biosimilar version of AbbVie's ABBV Humira al... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. With a biosimilar version of AbbVie's ABBV Humira al... | With a biosimilar version of AbbVie's ABBV Humira also under review in the United States, Pfizer expects potential U.S. approvals for up to four biosimilar products in 2019. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY... |
25,056 | 2019-03-12 00:00:00 UTC | Noteworthy Tuesday Option Activity: AMG, NRG, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-amg-nrg-abbv-2019-03-12 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Affiliated Managers Group Inc. (Symbol: AMG), where a total of 5,202 contracts have traded so far, representing approximately 520,200 underlying shares. That amounts to about 115.9% of AMG's average daily trading vol... | Especially high volume was seen for the $77.50 strike put option expiring March 15, 2019 , with 10,990 contracts trading so far today, representing approximately 1.1 million underlying shares of ABBV. Below is a chart showing NRG's trailing twelve month trading history, with the $34 strike highlighted in orange: And Ab... | Below is a chart showing NRG's trailing twelve month trading history, with the $34 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 34,650 contracts thus far today. Especially high volume was seen for the $77.50 strike put option expiring March 15, 2019 , with 10,990 contracts... | Especially high volume was seen for the $77.50 strike put option expiring March 15, 2019 , with 10,990 contracts trading so far today, representing approximately 1.1 million underlying shares of ABBV. Below is a chart showing NRG's trailing twelve month trading history, with the $34 strike highlighted in orange: And Ab... | Especially high volume was seen for the $77.50 strike put option expiring March 15, 2019 , with 10,990 contracts trading so far today, representing approximately 1.1 million underlying shares of ABBV. Below is a chart showing NRG's trailing twelve month trading history, with the $34 strike highlighted in orange: And Ab... |
25,057 | 2019-03-11 00:00:00 UTC | Should Value Investors Consider Abbvie (ABBV) Stock Now? | ABBV | https://www.nasdaq.com/articles/should-value-investors-consider-abbvie-abbv-stock-now-2019-03-11 | null | null | Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking ... | In this case, Abbvie's P/CF ratio of 15.6 is lower than the Zacks Large Cap Pharmaceuticals industry average of 15.8, which indicates that the stock is somewhat undervalued in this respect. Let's put Abbvie Inc . ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, o... | If we focus on the long-term PE trend, Abbvie's current PE level puts it below its midpoint of 14.6 over the past five years. You can see the consensus estimate trend and recent price action for the stock in the chart below: AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote This somewh... | ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. You can see the consen... | ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. If we focus on the lon... |
25,058 | 2019-03-11 00:00:00 UTC | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-but-lags-market%3A-what-you-should-know-2019-03-11 | null | null | AbbVie (ABBV) closed the most recent trading day at $78.08, moving +0.64% from the previous trading session. This change lagged the S&P 500's 1.47% gain on the day. Elsewhere, the Dow gained 0.79%, while the tech-heavy Nasdaq added 2.02%.
Prior to today's trading, shares of the drugmaker had lost 2.01% over the past mo... | AbbVie (ABBV) closed the most recent trading day at $78.08, moving +0.64% from the previous trading session. Investors will be hoping for strength from ABBV as it approaches its nex t earnings release. Investors should also note any recent changes to analyst estimates for ABBV. | AbbVie (ABBV) closed the most recent trading day at $78.08, moving +0.64% from the previous trading session. Investors will be hoping for strength from ABBV as it approaches its nex t earnings release. Investors should also note any recent changes to analyst estimates for ABBV. | AbbVie (ABBV) closed the most recent trading day at $78.08, moving +0.64% from the previous trading session. Investors will be hoping for strength from ABBV as it approaches its nex t earnings release. Investors should also note any recent changes to analyst estimates for ABBV. | Investors should also note any recent changes to analyst estimates for ABBV. ABBV is currently a Zacks Rank #3 (Hold). AbbVie (ABBV) closed the most recent trading day at $78.08, moving +0.64% from the previous trading session. |
25,059 | 2019-03-10 00:00:00 UTC | 4 Stocks to Buy With Dividends Yielding More Than 4% | ABBV | https://www.nasdaq.com/articles/4-stocks-buy-dividends-yielding-more-4-2019-03-10 | null | null | You won't have any trouble finding stocks with high dividend yields of 4% or more. There are hundreds of them. But many high-yield stocks are ones you shouldn't touch with a 10-foot pole. Their dividends are just too shaky.
There are some solid dividend stocks that yield 4% or more that do appear to be great picks to b... | Here's why AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , Medical Properties Trust (NYSE: MPW) , and Verizon Communications (NYSE: VZ) especially stand out. AbbVie Big drugmaker AbbVie pays a dividend that yields nearly 5.5%. AbbVie's immunology drug Humira remains the world's top-selling drug. | Here's why AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , Medical Properties Trust (NYSE: MPW) , and Verizon Communications (NYSE: VZ) especially stand out. AbbVie Big drugmaker AbbVie pays a dividend that yields nearly 5.5%. AbbVie's immunology drug Humira remains the world's top-selling drug. | Here's why AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , Medical Properties Trust (NYSE: MPW) , and Verizon Communications (NYSE: VZ) especially stand out. AbbVie, Brookfield Infrastructure Properties, Medical Properties Trust, and Verizon should appeal to investors seeking reliable high divide... | AbbVie, Brookfield Infrastructure Properties, Medical Properties Trust, and Verizon should appeal to investors seeking reliable high dividend yields. Here's why AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , Medical Properties Trust (NYSE: MPW) , and Verizon Communications (NYSE: VZ) especially ... |
25,060 | 2019-03-08 00:00:00 UTC | Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC | ABBV | https://www.nasdaq.com/articles/roches-rhhby-tecentriq-gets-ec-nod-for-first-line-nsclc-2019-03-08 | null | null | Swiss pharma company, RocheRHHBY announced that the European Commission (EC) has approved and granted marketing authorization to immuno-oncology drug, Tecentriq in combination with Avastin, paclitaxel and carboplatin for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC).... | Roche has a collaboration agreement with AbbVie, Inc. ABBV for Venclexta. Both the companies jointly commercialize the drug in the United States, while AbbVie commercializes it outside the United States. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Ana... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Spark Therapeutics, Inc. (ONCE): Free Stock Analysis Report To read this article on Zacks.com click here. Roche has a collaboration agreem... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Spark Therapeutics, Inc. (ONCE): Free Stock Analysis Report To read this article on Zacks.com click here. Roche has a collaboration agreem... | Roche has a collaboration agreement with AbbVie, Inc. ABBV for Venclexta. Both the companies jointly commercialize the drug in the United States, while AbbVie commercializes it outside the United States. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Ana... |
25,061 | 2019-03-07 00:00:00 UTC | Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed | ABBV | https://www.nasdaq.com/articles/vertexs-vx-445-triple-combo-cystic-fibrosis-trials-succeed-2019-03-07 | null | null | Vertex Pharmaceuticals IncorporatedVRTX announced that two phase III studies evaluating its next-generation CFTR corrector, VX-445 in combination with tezacaftor and Kalydeco (ivacaftor) met the primary endpoint of significant improvement in lung function in patients suffering from cystic fibrosis ("CF").
The improveme... | Meanwhile, many other companies like AbbVie ABBV and Proteostasis Therapeutics, Inc. PTI are also developing triple CFTR combinations for CF. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Proteostasis Therapeutics, Inc... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Proteostasis Therapeutics, Inc. (PTI): Free Stock Analysis Report Concert Pharmaceuticals, Inc. (CNCE): Free Stock Analysis Report To read this article on Zacks.com click h... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Proteostasis Therapeutics, Inc. (PTI): Free Stock Analysis Report Concert Pharmaceuticals, Inc. (CNCE): Free Stock Analysis Report To read this article on Zacks.com click h... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Proteostasis Therapeutics, Inc. (PTI): Free Stock Analysis Report Concert Pharmaceuticals, Inc. (CNCE): Free Stock Analysis Report To read this article on Zacks.com click h... |
25,062 | 2019-03-07 00:00:00 UTC | 2 Biotech Stocks With Major Incoming Catalysts | ABBV | https://www.nasdaq.com/articles/2-biotech-stocks-major-incoming-catalysts-2019-03-07 | null | null | The end of the first quarter is just a few weeks away and more than a few biotechs still haven't delivered the important clinical trial results they told investors to expect before the end of the period. The clock's ticking for Axsome Therapeutics (NASDAQ: AXSM) , Galapagos (NASDAQ: GLPG) and their experimental treatme... | Humira is one of several older rheumatoid arthritis treatments, and it raked in $19.9 billion for AbbVie (NYSE: ABBV) in 2018. AbbVie's JAK inhibitor, upadacitinib, is receiving a priority review that the FDA should wrap up in the third quarter. Physicians and pharmacists generally issue stern warnings not to mix the c... | Humira is one of several older rheumatoid arthritis treatments, and it raked in $19.9 billion for AbbVie (NYSE: ABBV) in 2018. AbbVie's JAK inhibitor, upadacitinib, is receiving a priority review that the FDA should wrap up in the third quarter. Galapagos: Fingers crossed Galapagos and its collaboration partner, Gilead... | Humira is one of several older rheumatoid arthritis treatments, and it raked in $19.9 billion for AbbVie (NYSE: ABBV) in 2018. AbbVie's JAK inhibitor, upadacitinib, is receiving a priority review that the FDA should wrap up in the third quarter. The end of the first quarter is just a few weeks away and more than a few ... | Humira is one of several older rheumatoid arthritis treatments, and it raked in $19.9 billion for AbbVie (NYSE: ABBV) in 2018. AbbVie's JAK inhibitor, upadacitinib, is receiving a priority review that the FDA should wrap up in the third quarter. The end of the first quarter is just a few weeks away and more than a few ... |
25,063 | 2019-03-07 00:00:00 UTC | The Kiplinger Dividend 15 Is On a Roll | ABBV | https://www.nasdaq.com/articles/kiplinger-dividend-15-roll-2019-03-07 | null | null | The Kiplinger Dividend 15 , our favorite stocks for dividend income, have bounced back nicely from the 2018 correction. The 15 stocks have an avera ge dividend yield of 3.7%, compared with 2.0% for Standard & Poor's 500-stock index. Since we last visited the Dividend 15 in our December issue, the stocks have returned a... | Our biggest loser was pharmaceutical giant AbbVie ( ABBV ), down 9.7% since mid October. But AbbVie has a strong pipeline of new drugs. The soaring share price has pushed Realty Income's yield below our 4% threshold for high-yield dividend stocks . | Our biggest loser was pharmaceutical giant AbbVie ( ABBV ), down 9.7% since mid October. But AbbVie has a strong pipeline of new drugs. The Kiplinger Dividend 15 , our favorite stocks for dividend income, have bounced back nicely from the 2018 correction. | Our biggest loser was pharmaceutical giant AbbVie ( ABBV ), down 9.7% since mid October. But AbbVie has a strong pipeline of new drugs. The Kiplinger Dividend 15 , our favorite stocks for dividend income, have bounced back nicely from the 2018 correction. | But AbbVie has a strong pipeline of new drugs. Our biggest loser was pharmaceutical giant AbbVie ( ABBV ), down 9.7% since mid October. All 15 stocks have raised their dividends over the past 12 months. |
25,064 | 2019-03-06 00:00:00 UTC | Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice | ABBV | https://www.nasdaq.com/articles/are-you-looking-for-a-high-growth-dividend-stock-abbvie-abbv-could-be-a-great-choice-1 | null | null | All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
While cash flow can come from bond interest or interest fro... | AbbVie in Focus Headquartered in North Chicago, AbbVie (ABBV) is a Medical stock that has seen a price change of -14.41% so far this year. Over the last 5 years, AbbVie has increased its dividend 5 times on a year-over-year basis for an average annual increase of 18.92%. Right now, AbbVie's payout ratio is 49%, which m... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie in Focus Headquartered in North Chicago, AbbVie (ABBV) is a Medical stock that has seen a price change of -14.41% so far this year. Over the last 5 years, AbbVie has increased its dividend 5... | AbbVie in Focus Headquartered in North Chicago, AbbVie (ABBV) is a Medical stock that has seen a price change of -14.41% so far this year. Over the last 5 years, AbbVie has increased its dividend 5 times on a year-over-year basis for an average annual increase of 18.92%. Right now, AbbVie's payout ratio is 49%, which m... | AbbVie in Focus Headquartered in North Chicago, AbbVie (ABBV) is a Medical stock that has seen a price change of -14.41% so far this year. Over the last 5 years, AbbVie has increased its dividend 5 times on a year-over-year basis for an average annual increase of 18.92%. Right now, AbbVie's payout ratio is 49%, which m... |
25,065 | 2019-03-05 00:00:00 UTC | The Zacks Analyst Blog Highlights: Intel, AbbVie, United Technologies, Simon Property and FirstEnergy | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-intel-abbvie-united-technologies-simon-property-and | null | null | For Immediate Release
Chicago, IL -March 5, 2019 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: IntelINTC , AbbVieABBV , Unite... | The Zacks analyst thinks AbbVie's key drug, Humira has been performing well in the United States based on strong demand trends despite new competition. Stocks recently featured in the blog include: IntelINTC , AbbVieABBV , United TechnologiesUTX , Simon Property GroupSPG and FirstEnergyFE . Here are highlights from Mon... | Here are highlights from Monday's Analyst Blog: Top Research Reports for Intel, AbbVie and United Technologies The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intel, AbbVie and United Technologies. Click t... | Here are highlights from Monday's Analyst Blog: Top Research Reports for Intel, AbbVie and United Technologies The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intel, AbbVie and United Technologies. Click t... | Here are highlights from Monday's Analyst Blog: Top Research Reports for Intel, AbbVie and United Technologies The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intel, AbbVie and United Technologies. The Zac... |
25,066 | 2019-03-04 00:00:00 UTC | AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab | ABBV | https://www.nasdaq.com/articles/abbvie-gets-chmp-nod-for-psoriasis-candidate-risankizumab-2019-03-04 | null | null | AbbVie, Inc.ABBV announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion, recommending marketing approval for risankizumab, its investigational interleukin-23 (IL-23) inhibitor, which has been developed for the treatment of moderate-to-seve... | Data from these studies showed that more than half of the patients receiving risankizumab achieved complete skin clearance at one year.AbbVie's application will now be reviewed by the European Commission, which will announce its decision in two months' time. AbbVie has developed risankizumab in collaboration with Boehr... | AbbVie, Inc.ABBV announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion, recommending marketing approval for risankizumab, its investigational interleukin-23 (IL-23) inhibitor, which has been developed for the treatment of moderate-to-seve... | AbbVie, Inc.ABBV announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion, recommending marketing approval for risankizumab, its investigational interleukin-23 (IL-23) inhibitor, which has been developed for the treatment of moderate-to-seve... | With Humira accounting for around 61% of AbbVie's sales, the entry of biosimilars will have a huge impact on the company's financials. AbbVie, Inc.ABBV announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion, recommending marketing approval... |
25,067 | 2019-03-04 00:00:00 UTC | Here's Why Voyager Therapeutics Stock Rose as Much as 13% Today | ABBV | https://www.nasdaq.com/articles/heres-why-voyager-therapeutics-stock-rose-much-13-today-2019-03-04 | null | null | What happened
Shares of Voyager Therapeutics (NASDAQ: VYGR) jumped as much as 13% today after the nascent field of gene therapy saw yet another acquisition this week. Biogen offered to buy Nightstar Therapeutics for roughly $877 million . The deal would give the biotech giant access to a promising late-stage gene thera... | It followed that up by announcing a sizable deal with AbbVie in late February. Voyager Therapeutics can also expand its partnership with AbbVie to other clinical candidates. The deal would give the biotech giant access to a promising late-stage gene therapy candidate aimed at treating a rare eye disease. | It followed that up by announcing a sizable deal with AbbVie in late February. Voyager Therapeutics can also expand its partnership with AbbVie to other clinical candidates. While Voyager Therapeutics isn't focused on gene therapies for vision-related ailments, investors are speculating the biopharma's recent deals wit... | It followed that up by announcing a sizable deal with AbbVie in late February. Voyager Therapeutics can also expand its partnership with AbbVie to other clinical candidates. While Voyager Therapeutics isn't focused on gene therapies for vision-related ailments, investors are speculating the biopharma's recent deals wit... | Voyager Therapeutics can also expand its partnership with AbbVie to other clinical candidates. It followed that up by announcing a sizable deal with AbbVie in late February. What happened Shares of Voyager Therapeutics (NASDAQ: VYGR) jumped as much as 13% today after the nascent field of gene therapy saw yet another ac... |
25,068 | 2019-02-28 00:00:00 UTC | 3 Top Stocks With High Dividend Yields | ABBV | https://www.nasdaq.com/articles/3-top-stocks-high-dividend-yields-2019-02-28 | null | null | High-yield stocks , or dividend stocks that dole out yields above that of the S&P 500 or an income benchmark like the U.S. Treasury Note, can hugely boost your income and build wealth in the long run. Of course, not all high-yield stocks are safe, but the ones that offer strong yields backed by a steady dividend payout... | Meanwhile, investors can sit back and collect AbbVie's monstrous dividend yield of 5.32% as the biotech's next set of growth products continues to come online. Plane leasing company Aircastle (NYSE: AYR) , clean-energy play Brookfield Renewable Partners (NYSE: BEP) , and pharma giant AbbVie (NYSE: ABBV) are three such ... | Plane leasing company Aircastle (NYSE: AYR) , clean-energy play Brookfield Renewable Partners (NYSE: BEP) , and pharma giant AbbVie (NYSE: ABBV) are three such dividend stocks our Motley Fool contributors recommend. See the 10 stocks *Stock Advisor returns as of February 1, 2019 George Budwell owns shares of AbbVie. Bi... | Plane leasing company Aircastle (NYSE: AYR) , clean-energy play Brookfield Renewable Partners (NYSE: BEP) , and pharma giant AbbVie (NYSE: ABBV) are three such dividend stocks our Motley Fool contributors recommend. Big biotech's black sheep George Budwell (AbbVie): During AbbVie's first five full years as an independe... | Big biotech's black sheep George Budwell (AbbVie): During AbbVie's first five full years as an independent entity, the company produced a total return on capital for early-bird shareholders of 333% (including dividends). Plane leasing company Aircastle (NYSE: AYR) , clean-energy play Brookfield Renewable Partners (NYSE... |
25,069 | 2019-02-28 00:00:00 UTC | IYH, ABT, MDT, ABBV: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/iyh-abt-mdt-abbv-large-outflows-detected-etf-2019-02-28 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $58.2 million dollar outflow -- that's a 2.4% decrease week over week (from 12,450,000 to 12,150,000). Among ... | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price... | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price... | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price... |
25,070 | 2019-02-27 00:00:00 UTC | Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You | ABBV | https://www.nasdaq.com/articles/big-pharmas-showdown-congress-over-drug-pricing-what-it-really-means-you-2019-02-27 | null | null | There were some fireworks in Washington, D.C., on Tuesday. And they went off in the Dirksen Senate Office Building.
Seven executives of big pharma faced a grilling from members of the U.S. Senate Committee on Finance, as it looked into how to lower drug prices in the United States. CEOs from AbbVie (NYSE: ABBV) , Astra... | CEOs from AbbVie (NYSE: ABBV) , AstraZeneca (NYSE: AZN) , Bristol-Myers Squibb (NYSE: BMY) , Merck (NYSE: MRK) , Pfizer (NYSE: PFE) , and Sanofi (NASDAQ: SNY) , along with an executive vice president from Johnson & Johnson (NYSE: JNJ) , responded to the committee's sometimes heated questions. He attacked AbbVie for usi... | CEOs from AbbVie (NYSE: ABBV) , AstraZeneca (NYSE: AZN) , Bristol-Myers Squibb (NYSE: BMY) , Merck (NYSE: MRK) , Pfizer (NYSE: PFE) , and Sanofi (NASDAQ: SNY) , along with an executive vice president from Johnson & Johnson (NYSE: JNJ) , responded to the committee's sometimes heated questions. The Trump administration h... | The Trump administration has proposed such an approach, but AbbVie CEO Rick Gonzalez warned that his company would have to cut back its investment in developing new drugs if U.S. drug prices fell to the levels charged in other countries. CEOs from AbbVie (NYSE: ABBV) , AstraZeneca (NYSE: AZN) , Bristol-Myers Squibb (NY... | CEOs from AbbVie (NYSE: ABBV) , AstraZeneca (NYSE: AZN) , Bristol-Myers Squibb (NYSE: BMY) , Merck (NYSE: MRK) , Pfizer (NYSE: PFE) , and Sanofi (NASDAQ: SNY) , along with an executive vice president from Johnson & Johnson (NYSE: JNJ) , responded to the committee's sometimes heated questions. He attacked AbbVie for usi... |
25,071 | 2019-02-26 00:00:00 UTC | U.S. senators tell drug company execs pricing is 'morally repugnant' | ABBV | https://www.nasdaq.com/articles/us-senators-tell-drug-company-execs-pricing-morally-repugnant-2019-02-26 | null | null | By Yasmeen Abutaleb and Michael Erman
WASHINGTON/NEW YORK, Feb 26 () - U.S. senators called drug pricing practices "morally repugnant" and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at a Senate hearing on the rising costs of prescription medi... | Senators took aim in particular at Abbvie Inc Chief Executive Richard Gonzalez and his company's rheumatoid arthritis drug Humira - the world's top-selling prescription medicine. Senators from both parties targeted AbbVie's Gonzalez, with Wyden noting that the CEO's bonus was partially tied to Humira sales, which reach... | Senators took aim in particular at Abbvie Inc Chief Executive Richard Gonzalez and his company's rheumatoid arthritis drug Humira - the world's top-selling prescription medicine. Senators from both parties targeted AbbVie's Gonzalez, with Wyden noting that the CEO's bonus was partially tied to Humira sales, which reach... | Senators took aim in particular at Abbvie Inc Chief Executive Richard Gonzalez and his company's rheumatoid arthritis drug Humira - the world's top-selling prescription medicine. Senators from both parties targeted AbbVie's Gonzalez, with Wyden noting that the CEO's bonus was partially tied to Humira sales, which reach... | Senators took aim in particular at Abbvie Inc Chief Executive Richard Gonzalez and his company's rheumatoid arthritis drug Humira - the world's top-selling prescription medicine. Senators from both parties targeted AbbVie's Gonzalez, with Wyden noting that the CEO's bonus was partially tied to Humira sales, which reach... |
25,072 | 2019-02-26 00:00:00 UTC | Drug company execs to testify before U.S. Senate | ABBV | https://www.nasdaq.com/articles/drug-company-execs-testify-us-senate-2019-02-26 | null | null | By Yasmeen Abutaleb and Michael Erman
WASHINGTON/NEW YORK, Feb 26 () - Seven drug company executives will testify about rising prescription drug prices before a powerful U.S. Senate Committee on Tuesday, marking a sharp escalation in lawmakers' promises to address high medicine costs.
Executives from Abbvie Inc, AstraZ... | Executives from Abbvie Inc, AstraZeneca PLC, Sanofi SA, Pfizer Inc, Merck & Co, Johnson & Johnson and Bristol-Myers Squibb Co are all expected to answer questions from members of the U.S. Senate Finance Committee. The U.S. Department of Health and Human Services (HHS) last year rolled out a plan to lower drug prices an... | Executives from Abbvie Inc, AstraZeneca PLC, Sanofi SA, Pfizer Inc, Merck & Co, Johnson & Johnson and Bristol-Myers Squibb Co are all expected to answer questions from members of the U.S. Senate Finance Committee. Pharmaceutical companies have blamed high research and development costs for their prices and after-market... | Executives from Abbvie Inc, AstraZeneca PLC, Sanofi SA, Pfizer Inc, Merck & Co, Johnson & Johnson and Bristol-Myers Squibb Co are all expected to answer questions from members of the U.S. Senate Finance Committee. By Yasmeen Abutaleb and Michael Erman WASHINGTON/NEW YORK, Feb 26 () - Seven drug company executives will ... | Executives from Abbvie Inc, AstraZeneca PLC, Sanofi SA, Pfizer Inc, Merck & Co, Johnson & Johnson and Bristol-Myers Squibb Co are all expected to answer questions from members of the U.S. Senate Finance Committee. The U.S. Department of Health and Human Services (HHS) last year rolled out a plan to lower drug prices an... |
25,073 | 2019-02-26 00:00:00 UTC | 3 Top Dividend Stocks With Yields Over 5% | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-yields-over-5-2019-02-26 | null | null | If you are looking for dividend stocks with big yields, Enviva Partners LP (NYSE: EVA) , VEREIT Inc. (NYSE: VER) , and AbbVie Inc. (NYSE: ABBV) are worth a close look today. The stocks all offer a yield over 5% and there's a compelling story behind each name. From clean energy to healthcare, with a stopover in real est... | If you are looking for dividend stocks with big yields, Enviva Partners LP (NYSE: EVA) , VEREIT Inc. (NYSE: VER) , and AbbVie Inc. (NYSE: ABBV) are worth a close look today. A high-yield biotech bargain Keith Speights (AbbVie Inc.): If you like dividends, you should love AbbVie. And including its time as a part of Abbo... | If you are looking for dividend stocks with big yields, Enviva Partners LP (NYSE: EVA) , VEREIT Inc. (NYSE: VER) , and AbbVie Inc. (NYSE: ABBV) are worth a close look today. A high-yield biotech bargain Keith Speights (AbbVie Inc.): If you like dividends, you should love AbbVie. And including its time as a part of Abbo... | If you are looking for dividend stocks with big yields, Enviva Partners LP (NYSE: EVA) , VEREIT Inc. (NYSE: VER) , and AbbVie Inc. (NYSE: ABBV) are worth a close look today. But AbbVie isn't just a great dividend stock; it's also a pretty good bargain right now. A high-yield biotech bargain Keith Speights (AbbVie Inc.)... | But AbbVie isn't just a great dividend stock; it's also a pretty good bargain right now. If you are looking for dividend stocks with big yields, Enviva Partners LP (NYSE: EVA) , VEREIT Inc. (NYSE: VER) , and AbbVie Inc. (NYSE: ABBV) are worth a close look today. A high-yield biotech bargain Keith Speights (AbbVie Inc.)... |
25,074 | 2019-02-25 00:00:00 UTC | Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat | ABBV | https://www.nasdaq.com/articles/momenta-mnta-q4-loss-narrower-than-expected-revenues-beat-2019-02-25 | null | null | Shares of Momenta Pharmaceuticals Inc.MNTA gained 8.6% after the company reported better-than-expected results for the fourth quarter.
The company reported loss per share of 7 cents in the quarter (excluding restructuring charges), narrower than the Zacks Consensus Estimate of 46 cents and the year-ago loss of 18 cents... | As a result of its strategic review (results announced in October 2018), Momenta concluded to advance two late-stage biosimilar assets - M923, which is its wholly-owned proposed biosimilar to AbbVie's ABBV Humira, and M710, which is a proposed biosimilar to Regeneron's Eylea being developed in collaboration with Mylan.... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. As a result of i... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. As a result of i... | As a result of its strategic review (results announced in October 2018), Momenta concluded to advance two late-stage biosimilar assets - M923, which is its wholly-owned proposed biosimilar to AbbVie's ABBV Humira, and M710, which is a proposed biosimilar to Regeneron's Eylea being developed in collaboration with Mylan.... |
25,075 | 2019-02-25 00:00:00 UTC | The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-merck-design-roche-and-abbvie-2019-02-25 | null | null | For Immediate Release
Chicago, IL - February 25, 2019 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include:Merck MRK , Design Corp. I... | Meanwhile, the FDA granted priority review and accepted regulatory applications filed by Merck, Roche and AbbVie looking for approval of their respective pipeline candidates or line extensions of their marketed drugs. Stocks recently featured in the blog include:Merck MRK , Design Corp. IMDZ , Roche RHHBY and AbbVie AB... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Immune Design Corp. (IMDZ): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog ... | Meanwhile, the FDA granted priority review and accepted regulatory applications filed by Merck, Roche and AbbVie looking for approval of their respective pipeline candidates or line extensions of their marketed drugs. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV):... | Meanwhile, the FDA granted priority review and accepted regulatory applications filed by Merck, Roche and AbbVie looking for approval of their respective pipeline candidates or line extensions of their marketed drugs. Stocks recently featured in the blog include:Merck MRK , Design Corp. IMDZ , Roche RHHBY and AbbVie AB... |
25,076 | 2019-02-25 00:00:00 UTC | AbbVie Extends Deal With Voyager to Make Parkinson's Drugs | ABBV | https://www.nasdaq.com/articles/abbvie-extends-deal-with-voyager-to-make-parkinsons-drugs-2019-02-25 | null | null | AbbVie, Inc.ABBV announced an expansion of its global strategic collaboration and option agreement with small biotech Voyager Therapeutics, Inc. VYGR to develop potential gene therapies for Parkinson's disease (PD) and other synucleinopathies.
Per the deal, Voyager will develop vectorized antibodies targeting pathologi... | AbbVie, Inc.ABBV announced an expansion of its global strategic collaboration and option agreement with small biotech Voyager Therapeutics, Inc. VYGR to develop potential gene therapies for Parkinson's disease (PD) and other synucleinopathies. AbbVie has always been actively pursuing partnership deals and collaboration... | Per the deal, Voyager will develop vectorized antibodies in preclinical stage, after which AbbVie has an option to in-license the vectorized alpha-synuclein antibody program for further clinical development. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stoc... | AbbVie, Inc.ABBV announced an expansion of its global strategic collaboration and option agreement with small biotech Voyager Therapeutics, Inc. VYGR to develop potential gene therapies for Parkinson's disease (PD) and other synucleinopathies. Per the deal, Voyager will develop vectorized antibodies in preclinical stag... | AbbVie, Inc.ABBV announced an expansion of its global strategic collaboration and option agreement with small biotech Voyager Therapeutics, Inc. VYGR to develop potential gene therapies for Parkinson's disease (PD) and other synucleinopathies. Per the deal, Voyager will develop vectorized antibodies in preclinical stag... |
25,077 | 2019-02-24 00:00:00 UTC | Why Is AbbVie (ABBV) Down 6.8% Since Last Earnings Report? | ABBV | https://www.nasdaq.com/articles/why-is-abbvie-abbv-down-6.8-since-last-earnings-report-2019-02-24 | null | null | It has been about a month since the las t earnings report for AbbVie (ABBV). Shares have lost about 6.8% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is AbbVie due for a breakout? Before we dive into how investors and analysts have ... | In the quarter, AbbVie recorded an impairment charge of $2.75 per share on assets from the 2016 acquisition of Stemcentrx due to recent Rova-T clinical setbacks. It has been about a month since the las t earnings report for AbbVie (ABBV). Will the recent negative trend continue leading up to its next earnings release, ... | It has been about a month since the las t earnings report for AbbVie (ABBV). Will the recent negative trend continue leading up to its next earnings release, or is AbbVie due for a breakout? AbbVie Q4 Earnings & Sales Miss, Humira Ex-U.S. | It has been about a month since the las t earnings report for AbbVie (ABBV). Will the recent negative trend continue leading up to its next earnings release, or is AbbVie due for a breakout? AbbVie Q4 Earnings & Sales Miss, Humira Ex-U.S. | It has been about a month since the las t earnings report for AbbVie (ABBV). Will the recent negative trend continue leading up to its next earnings release, or is AbbVie due for a breakout? AbbVie Q4 Earnings & Sales Miss, Humira Ex-U.S. |
25,078 | 2019-02-22 00:00:00 UTC | Why Voyager Therapeutics Is Skyrocketing Today | ABBV | https://www.nasdaq.com/articles/why-voyager-therapeutics-skyrocketing-today-2019-02-22 | null | null | What happened
Shares of Voyager Therapeutics (NASDAQ: VYGR) were skyrocketing 21.7% higher as of 11:22 a.m. EST on Friday. The small biotech announced a collaboration with AbbVie (NYSE: ABBV) to develop vectorized antibodies to treat Parkinson's disease and other diseases characterized by the abnormal accumulation of m... | A partnership with a major drugmaker like AbbVie also helps boost investors' enthusiasm about the prospects for Voyager's experimental gene therapies. If phase 1 testing is successful, AbbVie then has an option to license the selected program for continued clinical development and future global commercialization. The s... | The small biotech announced a collaboration with AbbVie (NYSE: ABBV) to develop vectorized antibodies to treat Parkinson's disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein. If phase 1 testing is successful, AbbVie then has an option to license the selected progr... | The small biotech announced a collaboration with AbbVie (NYSE: ABBV) to develop vectorized antibodies to treat Parkinson's disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein. So what The most tangible impact of Voyager's deal with AbbVie is a nice infusion of cash... | If all goes well, AbbVie has the option to select one or more vectorized antibodies to move into phase 1 clinical studies. If phase 1 testing is successful, AbbVie then has an option to license the selected program for continued clinical development and future global commercialization. The small biotech announced a col... |
25,079 | 2019-02-22 00:00:00 UTC | Energy Sector Update for 02/22/2019: VYGR, ABBV | ABBV | https://www.nasdaq.com/articles/energy-sector-update-02222019-vygr-abbv-2019-02-22 | null | null | Voyager Therapeutics ( VYGR ), a gene therapy group targeting neurological diseases, and AbbVie ( ABBV ), a biopharmaceutical firm, disclosed Friday an exclusive global collaboration and agreement to develop and commercialize vectorized antibodies.
Shares of Voyager surged more than 21% intraday and the AbbVie stock al... | Voyager Therapeutics ( VYGR ), a gene therapy group targeting neurological diseases, and AbbVie ( ABBV ), a biopharmaceutical firm, disclosed Friday an exclusive global collaboration and agreement to develop and commercialize vectorized antibodies. "The expansion of AbbVie's partnership with Voyager represents the pote... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Voyager Therapeutics ( VYGR ), a gene therapy group targeting neurological diseases, and AbbVie ( ABBV ), a biopharmaceutical firm, disclosed Friday an exclusive global collaboration and... | Voyager Therapeutics ( VYGR ), a gene therapy group targeting neurological diseases, and AbbVie ( ABBV ), a biopharmaceutical firm, disclosed Friday an exclusive global collaboration and agreement to develop and commercialize vectorized antibodies. "The expansion of AbbVie's partnership with Voyager represents the pote... | Voyager Therapeutics ( VYGR ), a gene therapy group targeting neurological diseases, and AbbVie ( ABBV ), a biopharmaceutical firm, disclosed Friday an exclusive global collaboration and agreement to develop and commercialize vectorized antibodies. Shares of Voyager surged more than 21% intraday and the AbbVie stock al... |
25,080 | 2019-02-21 00:00:00 UTC | What Pharma Investors Need to Know About Pfizer's Latest Disaster | ABBV | https://www.nasdaq.com/articles/what-pharma-investors-need-know-about-pfizers-latest-disaster-2019-02-21 | null | null | Pfizer (NYSE: PFE) recently shared some unfortunate news related to its blockbuster anti-inflammation drug, Xeljanz. A safety problem for this popular tablet could open doors for similar treatments that AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are shepherding through late-stage development right now, or i... | A safety problem for this popular tablet could open doors for similar treatments that AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are shepherding through late-stage development right now, or it could spell trouble for the entire class of drugs. Xeljanz isn't the only drug of its class associated with lethal ... | A safety problem for this popular tablet could open doors for similar treatments that AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are shepherding through late-stage development right now, or it could spell trouble for the entire class of drugs. Xeljanz isn't the only drug of its class associated with lethal ... | A safety problem for this popular tablet could open doors for similar treatments that AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are shepherding through late-stage development right now, or it could spell trouble for the entire class of drugs. Xeljanz isn't the only drug of its class associated with lethal ... | Xeljanz isn't the only drug of its class associated with lethal blood clots, and there's a chance the Food and Drug Administration could try to hinder AbbVie and Gilead Sciences from launching another one. A safety problem for this popular tablet could open doors for similar treatments that AbbVie (NYSE: ABBV) and Gile... |
25,081 | 2019-02-20 00:00:00 UTC | Notable ETF Outflow Detected - IYH, ABT, MDT, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-iyh-abt-mdt-abbv-2019-02-20 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $68.2 million dollar outflow -- that's a 2.7% decrease week over week (from 12,800,000 to 12,450,000). Among ... | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Medtronic PLC (Symbol: MDT) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year pri... | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Medtronic PLC (Symbol: MDT) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year pri... | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Medtronic PLC (Symbol: MDT) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Medtronic PLC (Symbol: MDT) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year pri... |
25,082 | 2019-02-19 00:00:00 UTC | 2 Pharma Stocks in the Middle of an Oncology Sales Explosion | ABBV | https://www.nasdaq.com/articles/2-pharma-stocks-middle-oncology-sales-explosion-2019-02-19 | null | null | Global spending on cancer drugs has soared in recent years along with the number of expensive new treatments reaching patients in need of new options. Roche (NASDAQOTH: RHHBY) led the industry with around $26 billion in oncology sales last year, but losses from aging brands will soon push the Swiss pharmaceutical giant... | AstraZeneca (NYSE: AZN) and AbbVie (NYSE: ABBV) don't have the largest oncology businesses at the moment, but they reported more growth in 2018 than their peers. AbbVie: Exceeding expectations AbbVie's oncology presence has surged along with sales of two blood cancer drugs, Imbruvica and Venclexta. AbbVie may have just... | AstraZeneca (NYSE: AZN) and AbbVie (NYSE: ABBV) don't have the largest oncology businesses at the moment, but they reported more growth in 2018 than their peers. AbbVie: Exceeding expectations AbbVie's oncology presence has surged along with sales of two blood cancer drugs, Imbruvica and Venclexta. AbbVie may have just... | AstraZeneca (NYSE: AZN) and AbbVie (NYSE: ABBV) don't have the largest oncology businesses at the moment, but they reported more growth in 2018 than their peers. AbbVie: Exceeding expectations AbbVie's oncology presence has surged along with sales of two blood cancer drugs, Imbruvica and Venclexta. AbbVie may have just... | AbbVie may have just two big cancer drugs driving growth for its oncology segment, but they've got room to grow. AstraZeneca (NYSE: AZN) and AbbVie (NYSE: ABBV) don't have the largest oncology businesses at the moment, but they reported more growth in 2018 than their peers. AbbVie: Exceeding expectations AbbVie's oncol... |
25,083 | 2019-02-19 00:00:00 UTC | U.S. settles with Teva over keeping generic drugs off market | ABBV | https://www.nasdaq.com/articles/us-settles-teva-over-keeping-generic-drugs-market-2019-02-19 | null | null | WASHINGTON, Feb 19 () - The U.S. government has reached a settlement with Teva Pharmaceuticals Industries Ltd over charges that its agreements with rivals impeded consumer access to lower-priced generic drugs.
The Federal Trade Commission on Tuesday said it had settled three reverse payment fights with units of Teva, w... | In this instance, AbbVie Inc, which had acquired the drug, was accused of paying off Teva and another generic maker to again delay bringing out a cheaper version of the medicine. The agency also said it would press on with a lawsuit accusing AbbVie and a partner for filing baseless patent litigation claims. WASHINGTON,... | In this instance, AbbVie Inc, which had acquired the drug, was accused of paying off Teva and another generic maker to again delay bringing out a cheaper version of the medicine. The agency also said it would press on with a lawsuit accusing AbbVie and a partner for filing baseless patent litigation claims. The oldest ... | In this instance, AbbVie Inc, which had acquired the drug, was accused of paying off Teva and another generic maker to again delay bringing out a cheaper version of the medicine. The agency also said it would press on with a lawsuit accusing AbbVie and a partner for filing baseless patent litigation claims. The FTC has... | In this instance, AbbVie Inc, which had acquired the drug, was accused of paying off Teva and another generic maker to again delay bringing out a cheaper version of the medicine. The agency also said it would press on with a lawsuit accusing AbbVie and a partner for filing baseless patent litigation claims. The FTC has... |
25,084 | 2019-02-19 00:00:00 UTC | Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review | ABBV | https://www.nasdaq.com/articles/roches-rhhby-bla-for-lymphoma-drug-gets-priority-review-2019-02-19 | null | null | RocheRHHBY announced that the FDA has accepted the company's Biologics License Application (BLA) for anti-CD79b antibody drug conjugate (ADC) polatuzumab vedotin in combination with bendamustine plus Rituxan (BR), for the treatment of patients suffering from relapsed or refractory (R/R) diffuse large B-cell lymphoma (D... | A potential approval will boost Roche's hematology portfolio, which comprises approved drugs like MabThera/Rituxan, Tecentriq, Gazyva and Venclexta in collaboration with AbbVie ABBV . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Novart... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. A potential approval will boost Roche's hematology p... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. A potential approval will boost Roche's hematology p... | A potential approval will boost Roche's hematology portfolio, which comprises approved drugs like MabThera/Rituxan, Tecentriq, Gazyva and Venclexta in collaboration with AbbVie ABBV . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Novart... |
25,085 | 2019-02-17 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On David Dreman - 2/17/2019 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-david-dreman-2172019-2019-02-17 | null | null | The following are the top rated Healthcare stocks according to Validea's Contrarian Investor model based on the published strategy of David Dreman . This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.
EXELIXIS, INC. ( EXEL ) is a mid-cap value ... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are the top rated Healthcare stocks according to Valide... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's segments include triple net senior living communities t... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's segments include triple net senior living communities t... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are the top rated Healthcare stocks according to Valide... |
25,086 | 2019-02-16 00:00:00 UTC | These 3 Value Stocks Are Absurdly Cheap Right Now | ABBV | https://www.nasdaq.com/articles/these-3-value-stocks-are-absurdly-cheap-right-now-2019-02-16 | null | null | Value investing often ends up leading investors into just one or two out-of-favor sectors. You can't create a diversified portfolio going that route. So it's important to broaden your horizons, and at times your view of what constitutes value. Here are three stocks from vastly different industries that all look absurdl... | Here are three stocks from vastly different industries that all look absurdly cheap right now: Twitter (NYSE: TWTR ) in the technology space, ExxonMobil (NYSE: XOM) in energy, and Abbvie (NYSE: ABBV) in pharmaceuticals. A big pharma that's a big bargain Keith Speights (AbbVie) : I'd call a stock that trades for only 8.... | A big pharma that's a big bargain Keith Speights (AbbVie) : I'd call a stock that trades for only 8.5 times expected earnings inexpensive. Here are three stocks from vastly different industries that all look absurdly cheap right now: Twitter (NYSE: TWTR ) in the technology space, ExxonMobil (NYSE: XOM) in energy, and A... | Here are three stocks from vastly different industries that all look absurdly cheap right now: Twitter (NYSE: TWTR ) in the technology space, ExxonMobil (NYSE: XOM) in energy, and Abbvie (NYSE: ABBV) in pharmaceuticals. A big pharma that's a big bargain Keith Speights (AbbVie) : I'd call a stock that trades for only 8.... | In AbbVie's case, investors are worried about what will happen to the company's fortunes with its top-selling drug, Humira, facing competition from biosimilars. Here are three stocks from vastly different industries that all look absurdly cheap right now: Twitter (NYSE: TWTR ) in the technology space, ExxonMobil (NYSE:... |
25,087 | 2019-02-13 00:00:00 UTC | AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-is-a-top-dividend-stock-right-now%3A-should-you-buy-2019-02-13 | null | null | Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
Cash flow can come from bond interest, interest from other... | AbbVie in Focus AbbVie (ABBV) is headquartered in North Chicago, and is in the Medical sector. AbbVie has increased its dividend 5 times on a year-over-year basis over the last 5 years for an average annual increase of 18.92%. AbbVie's current payout ratio is 49%, meaning it paid out 49% of its trailing 12-month EPS as... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie in Focus AbbVie (ABBV) is headquartered in North Chicago, and is in the Medical sector. AbbVie has increased its dividend 5 times on a year-over-year basis over the last 5 years for an avera... | AbbVie in Focus AbbVie (ABBV) is headquartered in North Chicago, and is in the Medical sector. AbbVie has increased its dividend 5 times on a year-over-year basis over the last 5 years for an average annual increase of 18.92%. AbbVie's current payout ratio is 49%, meaning it paid out 49% of its trailing 12-month EPS as... | AbbVie in Focus AbbVie (ABBV) is headquartered in North Chicago, and is in the Medical sector. AbbVie has increased its dividend 5 times on a year-over-year basis over the last 5 years for an average annual increase of 18.92%. AbbVie's current payout ratio is 49%, meaning it paid out 49% of its trailing 12-month EPS as... |
25,088 | 2019-02-12 00:00:00 UTC | Better Buy: Gilead Sciences vs. Pfizer | ABBV | https://www.nasdaq.com/articles/better-buy-gilead-sciences-vs-pfizer-2019-02-12 | null | null | Neither Gilead Sciences (NASDAQ: GILD) nor Pfizer (NYSE: PFE) is expecting any sales growth this year. As a result, the market's already taken a swipe at both stocks, and they're starting to look like a bargain.
Both of these drugmakers have products that throw off huge cash flows, and they're committed to delivering a... | The company also expects around $900 million in lost sales because of competition with AbbVie (NYSE: ABBV) for a share of a hepatitis C antiviral (HCV) market that's been steadily shrinking. The case for Pfizer America's largest pharmaceutical company thinks the upcoming loss of market exclusivity for Lyrica will lop $... | The company also expects around $900 million in lost sales because of competition with AbbVie (NYSE: ABBV) for a share of a hepatitis C antiviral (HCV) market that's been steadily shrinking. The case for Gilead Sciences Gilead Sciences isn't expecting any top-line revenue growth in 2019 because expiring U.S. patents fo... | The company also expects around $900 million in lost sales because of competition with AbbVie (NYSE: ABBV) for a share of a hepatitis C antiviral (HCV) market that's been steadily shrinking. The case for Gilead Sciences Gilead Sciences isn't expecting any top-line revenue growth in 2019 because expiring U.S. patents fo... | The company also expects around $900 million in lost sales because of competition with AbbVie (NYSE: ABBV) for a share of a hepatitis C antiviral (HCV) market that's been steadily shrinking. The case for Gilead Sciences Gilead Sciences isn't expecting any top-line revenue growth in 2019 because expiring U.S. patents fo... |
25,089 | 2019-02-11 00:00:00 UTC | IWV, PEP, ABBV, AMGN: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/iwv-pep-abbv-amgn-etf-outflow-alert-2019-02-11 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $103.9 million dollar outflow -- that's a 1.1% decrease week over week (from 60,350,000 to 59,700,000). Among th... | Among the largest underlying components of IWV, in trading today PepsiCo Inc (Symbol: PEP) is off about 0.1%, AbbVie Inc (Symbol: ABBV) is off about 0.5%, and Amgen Inc (Symbol: AMGN) is up by about 0.1%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance... | Among the largest underlying components of IWV, in trading today PepsiCo Inc (Symbol: PEP) is off about 0.1%, AbbVie Inc (Symbol: ABBV) is off about 0.5%, and Amgen Inc (Symbol: AMGN) is up by about 0.1%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance... | Among the largest underlying components of IWV, in trading today PepsiCo Inc (Symbol: PEP) is off about 0.1%, AbbVie Inc (Symbol: ABBV) is off about 0.5%, and Amgen Inc (Symbol: AMGN) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one ... | Among the largest underlying components of IWV, in trading today PepsiCo Inc (Symbol: PEP) is off about 0.1%, AbbVie Inc (Symbol: ABBV) is off about 0.5%, and Amgen Inc (Symbol: AMGN) is up by about 0.1%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance... |
25,090 | 2019-02-11 00:00:00 UTC | 5 High-Growth Stocks Undervalued by the Market | ABBV | https://www.nasdaq.com/articles/5-high-growth-stocks-undervalued-by-the-market-2019-02-11 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
High-growth stocks draw the lion's share of the attention in financial media. These securities usually show higher levels of volatility and often represent the future of the American economy. Today, these equities often revolve around new technologies like ... | The following equities constitute some of the best stocks for combining growth with value: Source: Shutterstock AbbVie (ABBV) Drug equities don't often make lists of high-growth stocks. AbbVie (NYSE: ABBV ) formed in 2013 when it split from Abbott Laboratories (NYSE: ABT ). ABBV stock has suffered in recent months as i... | The following equities constitute some of the best stocks for combining growth with value: Source: Shutterstock AbbVie (ABBV) Drug equities don't often make lists of high-growth stocks. AbbVie (NYSE: ABBV ) formed in 2013 when it split from Abbott Laboratories (NYSE: ABT ). ABBV stock has suffered in recent months as i... | The following equities constitute some of the best stocks for combining growth with value: Source: Shutterstock AbbVie (ABBV) Drug equities don't often make lists of high-growth stocks. AbbVie (NYSE: ABBV ) formed in 2013 when it split from Abbott Laboratories (NYSE: ABT ). ABBV stock has suffered in recent months as i... | The following equities constitute some of the best stocks for combining growth with value: Source: Shutterstock AbbVie (ABBV) Drug equities don't often make lists of high-growth stocks. AbbVie (NYSE: ABBV ) formed in 2013 when it split from Abbott Laboratories (NYSE: ABT ). ABBV stock has suffered in recent months as i... |
25,091 | 2019-02-11 00:00:00 UTC | Here's Why Coherus BioSciences Rose 48.7% in January | ABBV | https://www.nasdaq.com/articles/heres-why-coherus-biosciences-rose-487-january-2019-02-11 | null | null | What happened
Shares of Coherus BioSciences (NASDAQ: CHRS) gained nearly 49% last month, according to data provided by S&P Global Market Intelligence . The company announced a global settlement with AbbVie that will allow the small-cap biopharma to commercialize a biosimilar to Humira, which was developed as CHS-1420. ... | The company announced a global settlement with AbbVie that will allow the small-cap biopharma to commercialize a biosimilar to Humira, which was developed as CHS-1420. Additionally, it will have to provide royalties to AbbVie on all domestic sales just for using the patent portfolio. After securing the licensing deal w... | After securing the licensing deal with AbbVie, Coherus BioSciences announced it was suing Amgen for infringing on its patents. The company announced a global settlement with AbbVie that will allow the small-cap biopharma to commercialize a biosimilar to Humira, which was developed as CHS-1420. Additionally, it will hav... | The company announced a global settlement with AbbVie that will allow the small-cap biopharma to commercialize a biosimilar to Humira, which was developed as CHS-1420. Additionally, it will have to provide royalties to AbbVie on all domestic sales just for using the patent portfolio. After securing the licensing deal w... | The company announced a global settlement with AbbVie that will allow the small-cap biopharma to commercialize a biosimilar to Humira, which was developed as CHS-1420. Additionally, it will have to provide royalties to AbbVie on all domestic sales just for using the patent portfolio. After securing the licensing deal w... |
25,092 | 2019-02-09 00:00:00 UTC | Here's Why AbbVie's Stock Tanked in January | ABBV | https://www.nasdaq.com/articles/heres-why-abbvies-stock-tanked-january-2019-02-09 | null | null | What happened
Unlike the vast majority of biopharma stocks, AbbVie 's (NYSE: ABBV) stock actually lost ground in January. The drugmaker's shares, in fact, fell by an unsightly 12.9% during the first month of the new year, according to data from S&P Global Market Intelligence .
What went wrong for this top biopharma las... | AbbVie apparently decided to write-off this costly acquisition after Rova-T repeatedly failed to hit the mark as a later-line lung cancer treatment last year. What happened Unlike the vast majority of biopharma stocks, AbbVie 's (NYSE: ABBV) stock actually lost ground in January. AbbVie's January swoon can be directly ... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. What happened Unlike the vast majority of biopharma stocks, AbbVie 's (NYSE: ABBV) stock actually lost ground in January. AbbVie's January swoon can be directly attributed to its disappo... | What happened Unlike the vast majority of biopharma stocks, AbbVie 's (NYSE: ABBV) stock actually lost ground in January. Topping it off, AbbVie also noted that international sales of its flagship anti-inflammatory medicine Humira fell by a whopping 14.8% year over year as a result of biosimilar competition in certain ... | See the 10 stocks *Stock Advisor returns as of January 31, 2019 George Budwell owns shares of AbbVie. What happened Unlike the vast majority of biopharma stocks, AbbVie 's (NYSE: ABBV) stock actually lost ground in January. AbbVie's January swoon can be directly attributed to its disappointing fourth-quarter earnings r... |
25,093 | 2019-02-07 00:00:00 UTC | ABBV March 29th Options Begin Trading | ABBV | https://www.nasdaq.com/articles/abbv-march-29th-options-begin-trading-2019-02-07 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the March 29th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new March 29th contracts and identified one put and one call contract of particular interest.
The put contrac... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $80.50 strike highlighted in red: Considering the fact that the $80.50 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possi... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $72.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $80.50 strike price has a current bid of 56 cents. Below is a chart showing AB... | At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new March 29th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $80.50 strike highlighted in red: Consider... |
25,094 | 2019-02-06 00:00:00 UTC | Pfizer CEO Bourla plans to testify at Senate drug pricing hearing | ABBV | https://www.nasdaq.com/articles/pfizer-ceo-bourla-plans-testify-senate-drug-pricing-hearing-2019-02-06 | null | null | NEW YORK, Feb 6 () - U.S. drugmaker Pfizer Inc said on Wednesday that its Chief Executive Albert Bourla plans to testify later this month at a Senate hearing examining rising prescription drug prices.
Republican Senator Chuck Grassley, chairman of the Senate Finance Committee, and Democratic Senator Ron Wyden, ranking ... | The other companies invited to send executives are AbbVie Inc, AstraZeneca Plc , Bristol-Myers Squibb Co, Johnson & Johnson and Sanofi SA. NEW YORK, Feb 6 () - U.S. drugmaker Pfizer Inc said on Wednesday that its Chief Executive Albert Bourla plans to testify later this month at a Senate hearing examining rising prescr... | The other companies invited to send executives are AbbVie Inc, AstraZeneca Plc , Bristol-Myers Squibb Co, Johnson & Johnson and Sanofi SA. NEW YORK, Feb 6 () - U.S. drugmaker Pfizer Inc said on Wednesday that its Chief Executive Albert Bourla plans to testify later this month at a Senate hearing examining rising prescr... | The other companies invited to send executives are AbbVie Inc, AstraZeneca Plc , Bristol-Myers Squibb Co, Johnson & Johnson and Sanofi SA. NEW YORK, Feb 6 () - U.S. drugmaker Pfizer Inc said on Wednesday that its Chief Executive Albert Bourla plans to testify later this month at a Senate hearing examining rising prescr... | The other companies invited to send executives are AbbVie Inc, AstraZeneca Plc , Bristol-Myers Squibb Co, Johnson & Johnson and Sanofi SA. NEW YORK, Feb 6 () - U.S. drugmaker Pfizer Inc said on Wednesday that its Chief Executive Albert Bourla plans to testify later this month at a Senate hearing examining rising prescr... |
25,095 | 2019-02-05 00:00:00 UTC | Merck CEO Frazier plans to testify at Senate drug pricing hearing | ABBV | https://www.nasdaq.com/articles/merck-ceo-frazier-plans-testify-senate-drug-pricing-hearing-2019-02-05 | null | null | By Michael Erman and Yasmeen Abutaleb
NEW YORK/WASHINGTON, Feb 5 () - U.S. drugmaker Merck & Co Inc said on Tuesday that its Chief Executive Ken Frazier plans to testify at a Senate hearing later this month examining rising prescription drug prices.
Republican Senator Chuck Grassley, chairman of the Senate Finance Comm... | The others are AbbVie Inc, AstraZeneca Plc , Bristol-Myers Squibb Co, Johnson & Johnson, Pfizer Inc and Sanofi SA. Pfizer, Bristol-Myers, and J&J did not immediately have a statement on the invitation to testify, while AbbVie did not respond to a request for comment. They nonetheless increased prices on hundreds of dru... | They nonetheless increased prices on hundreds of drugs in January, including a 6.2 percent increase on the world's top-selling drug - AbbVie's rheumatoid arthritis treatment Humira - and hikes on insulin prices by Sanofi and Novo Nordisk. The others are AbbVie Inc, AstraZeneca Plc , Bristol-Myers Squibb Co, Johnson & J... | They nonetheless increased prices on hundreds of drugs in January, including a 6.2 percent increase on the world's top-selling drug - AbbVie's rheumatoid arthritis treatment Humira - and hikes on insulin prices by Sanofi and Novo Nordisk. The others are AbbVie Inc, AstraZeneca Plc , Bristol-Myers Squibb Co, Johnson & J... | The others are AbbVie Inc, AstraZeneca Plc , Bristol-Myers Squibb Co, Johnson & Johnson, Pfizer Inc and Sanofi SA. Pfizer, Bristol-Myers, and J&J did not immediately have a statement on the invitation to testify, while AbbVie did not respond to a request for comment. They nonetheless increased prices on hundreds of dru... |
25,096 | 2019-02-05 00:00:00 UTC | Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies | ABBV | https://www.nasdaq.com/articles/lilly-incytes-olumiant-meets-endpoint-in-eczema-studies-2019-02-05 | null | null | Eli Lilly and CompanyLLY and Incyte Corporation INCY announced positive top-line data from two late-stage studies evaluating their oral JAK inhibitor, Olumiant (baricitinib), as monotherapy for moderate-to-severe atopic dermatitis ("AD"), a type of eczema. Data from the phase III studies - BREEZE-AD1 and BREEZE-AD2 - s... | Regeneron Pharmaceuticals and Sanofi's Dupixent is approved for treating AD since 2017 while AbbVie ABBV and Pfizer PFE are developing their respective candidates for the indication in late-stage studies.. Eli Lilly and Company Price Eli Lilly and Company Price | Eli Lilly and Company Quote Zacks Rank Lilly currently c... | Regeneron Pharmaceuticals and Sanofi's Dupixent is approved for treating AD since 2017 while AbbVie ABBV and Pfizer PFE are developing their respective candidates for the indication in late-stage studies.. Eli Lilly and Company Price Eli Lilly and Company Price | Eli Lilly and Company Quote Zacks Rank Lilly currently c... | Regeneron Pharmaceuticals and Sanofi's Dupixent is approved for treating AD since 2017 while AbbVie ABBV and Pfizer PFE are developing their respective candidates for the indication in late-stage studies.. Eli Lilly and Company Price Eli Lilly and Company Price | Eli Lilly and Company Quote Zacks Rank Lilly currently c... | Regeneron Pharmaceuticals and Sanofi's Dupixent is approved for treating AD since 2017 while AbbVie ABBV and Pfizer PFE are developing their respective candidates for the indication in late-stage studies.. Eli Lilly and Company Price Eli Lilly and Company Price | Eli Lilly and Company Quote Zacks Rank Lilly currently c... |
25,097 | 2019-02-05 00:00:00 UTC | 3 Biotech Stocks That Pay Solid Dividends | ABBV | https://www.nasdaq.com/articles/3-biotech-stocks-that-pay-solid-dividends-2019-02-05 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Although many biotech stocks have been hit hard at the start of 2019 while the general market has rallied, this underperformance in the biotechnology space has presented at least two key benefits for investors looking to invest in the area.
First, and perha... | AbbVie reported fourth-quarter adjusted profits that grew a solid 28% over last year; at $1.90 a share, the company achieved its guidance for the quarter. Source: Shutterstock AbbVie (ABBV) AbbVie (NYSE: ABBV ) trades at a modest price-to-earnings ratio of 21X, while shares yield 5.45%. Although short-term investors mi... | Source: Shutterstock AbbVie (ABBV) AbbVie (NYSE: ABBV ) trades at a modest price-to-earnings ratio of 21X, while shares yield 5.45%. Although short-term investors might be concerned that ABBV shares have been on a downtrend since topping in May 2018 at $122, there is still plenty of longer-term potential in ABBV to be ... | Source: Shutterstock AbbVie (ABBV) AbbVie (NYSE: ABBV ) trades at a modest price-to-earnings ratio of 21X, while shares yield 5.45%. Although short-term investors might be concerned that ABBV shares have been on a downtrend since topping in May 2018 at $122, there is still plenty of longer-term potential in ABBV to be ... | Source: Shutterstock AbbVie (ABBV) AbbVie (NYSE: ABBV ) trades at a modest price-to-earnings ratio of 21X, while shares yield 5.45%. Although short-term investors might be concerned that ABBV shares have been on a downtrend since topping in May 2018 at $122, there is still plenty of longer-term potential in ABBV to be ... |
25,098 | 2019-02-05 00:00:00 UTC | Merck CEO Frazier to testify at Senate drug pricing hearing | ABBV | https://www.nasdaq.com/articles/merck-ceo-frazier-testify-senate-drug-pricing-hearing-2019-02-05 | null | null | By Michael Erman and Yasmeen Abutaleb
NEW YORK/WASHINGTON, Feb 5 () - U.S. drugmaker Merck & Co Inc said on Tuesday that its Chief Executive Ken Frazier plans to testify at a Senate hearing later this month examining rising prescription drug prices.
Republican Senator Chuck Grassley, chairman of the Senate Finance Comm... | The others are AbbVie Inc, AstraZeneca Plc , Bristol-Myers Squibb Co, Johnson & Johnson, Pfizer Inc and Sanofi SA. Pfizer, Bristol-Myers, and J&J did not immediately have a statement on the invitation to testify, while AbbVie did not respond to a request for comment. They nonetheless increased prices on hundreds of dru... | They nonetheless increased prices on hundreds of drugs in January, including a 6.2 percent increase on the world's top-selling drug - AbbVie's rheumatoid arthritis treatment Humira - and hikes on insulin prices by Sanofi and Novo Nordisk. The others are AbbVie Inc, AstraZeneca Plc , Bristol-Myers Squibb Co, Johnson & J... | They nonetheless increased prices on hundreds of drugs in January, including a 6.2 percent increase on the world's top-selling drug - AbbVie's rheumatoid arthritis treatment Humira - and hikes on insulin prices by Sanofi and Novo Nordisk. The others are AbbVie Inc, AstraZeneca Plc , Bristol-Myers Squibb Co, Johnson & J... | The others are AbbVie Inc, AstraZeneca Plc , Bristol-Myers Squibb Co, Johnson & Johnson, Pfizer Inc and Sanofi SA. Pfizer, Bristol-Myers, and J&J did not immediately have a statement on the invitation to testify, while AbbVie did not respond to a request for comment. They nonetheless increased prices on hundreds of dru... |
25,099 | 2019-02-04 00:00:00 UTC | Powerful U.S. Senate committee invites pharma execs to testify | ABBV | https://www.nasdaq.com/articles/powerful-us-senate-committee-invites-pharma-execs-testify-2019-02-04 | null | null | WASHINGTON, Feb 4 () - A powerful U.S. Senate committee on Monday invited seven pharmaceutical companies to testify at a hearing later this month examining rising prescription drug prices.
Republican Senator Chuck Grassley, chairman of the Senate Finance Committee, and Democratic Senator Ron Wyden, ranking member of th... | Republican Senator Chuck Grassley, chairman of the Senate Finance Committee, and Democratic Senator Ron Wyden, ranking member of the committee, invited executives from AbbVie Inc, AstraZeneca PLC, Bristol-Myers Squibb Co, Johnson & Johnson, Merck & Co Inc, Pfizer Inc and Sanofi SA. WASHINGTON, Feb 4 () - A powerful U.S... | Republican Senator Chuck Grassley, chairman of the Senate Finance Committee, and Democratic Senator Ron Wyden, ranking member of the committee, invited executives from AbbVie Inc, AstraZeneca PLC, Bristol-Myers Squibb Co, Johnson & Johnson, Merck & Co Inc, Pfizer Inc and Sanofi SA. WASHINGTON, Feb 4 () - A powerful U.S... | Republican Senator Chuck Grassley, chairman of the Senate Finance Committee, and Democratic Senator Ron Wyden, ranking member of the committee, invited executives from AbbVie Inc, AstraZeneca PLC, Bristol-Myers Squibb Co, Johnson & Johnson, Merck & Co Inc, Pfizer Inc and Sanofi SA. WASHINGTON, Feb 4 () - A powerful U.S... | Republican Senator Chuck Grassley, chairman of the Senate Finance Committee, and Democratic Senator Ron Wyden, ranking member of the committee, invited executives from AbbVie Inc, AstraZeneca PLC, Bristol-Myers Squibb Co, Johnson & Johnson, Merck & Co Inc, Pfizer Inc and Sanofi SA. WASHINGTON, Feb 4 () - A powerful U.S... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.